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MODULATION OF ANGIOGENESIS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to U.S. Provisional Appli-
cation Ser. No. 60/764,269 filed Feb. 1, 2006, the disclosure 
of which is incorporated herein by reference. 
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ity in a subject are provided. The methods include adminis-
tering to the subject a compound that regulates the bioavail-
ability or biological activity ofVEGF or PlGF by modulating 
the availability of a VEGF or PLGF inactivating agent. The 
administering is sufficient to treat or prevent the condition in 
the subject. 
The inactivating agent generally forms a complex with 
VEGF or PlGF by binding to VEGF or PlGF. A compound 
provided herein can modulate VEGF or PlGF bioavailability 
TECHNICAL FIELD 
This invention relates to compounds, compositions, and 
methods for the treatment of traits, diseases and conditions 
that respond to the modulation of angiogenic growth factor 
bioavailability or biological activity. 
10 or biological activity by preventing, inhibiting or disrupting 
the formation of the complex. In one aspect, this is accom-
plished by decreasing the amount of the agent, such as by 
regulating the expression of the agent. In other aspects, pre-
venting, inhibiting or disrupting the formation of the complex 
BACKGROUND 
15 includes binding of the compound with complexed or uncom-
plexed inactivating agent. VEGF includes VEGF-A, VEGF-
B, VEGF-C andVEGF-DandPlGF includes PlGF-1 or PlGF-
2. 
In one aspect, the agent comprises a VEGFR1, VEGFR2 or 
20 VEGFR3 polypeptide. Exemplary VEGFR1 polypeptides are 
encoded by the fms-like tyrosine kinase (Flt-1) gene. Exem-
plary polypeptides include isoforms such as sflt-1 and mbflt-
1. 
The formation of new blood vessels either from differen-
tiating endothelial cells during embryonic development (vas-
culogenesis) or from pre-existing vessels during adult life 
(angiogenesis) is an essential feature of organ development, 
reproduction, and wound healing in higher organisms. Angio-
genesis is also necessary for certain pathological processes 
including tumorigenesis and retinopathy. While several 25 
growth factors can stimulate angiogenesis vascular endothe-
lial growth factor (VEGF) is a potent angiogenic factor that 
acts via the endothelial cell-specific receptor tyrosine kinases 
fms-like tyrosine kinase (Fltl) and fetal liver kinase (Flk1) 
(also designated KDR). These two VEGF receptors and a 30 
third orphan receptor, Flt4 constitute a subfamily of class III 
receptor tyrosine kinases that contain seven extracellular 
immunoglobulin-like domains and a split intracellular 
tyrosine kinase domain. These three receptors have 31-36% 
amino acid identity in their extracellular ligand-binding 35 
domains. 
Conditions associated with decreased vascularity include 
ocular disorders, preeclampsia, cerebrovascular disorders, 
cardiovascular disorders, systemic hypertension, peripheral 
vascular disease, vascular regeneration/recovery, and wound 
healing disorders. 
In one embodiment, the compound comprises a double 
stranded nucleic acid molecule having one strand that is at 
least 95% complementary to at least a portion of a nucleic 
acid sequence encoding the agent. In one aspect, the nucleic 
acid molecule comprises an interfering RNA molecule 
selected from shRNA, siRNA and miRNA. The length of the 
interfering RNA can be 10 to 80, 10 to 70, 10 to 60, 10 to 50, 
10 to 40, or 10 to 30 nucleotides in length. 
VEGF is a homodimeric, cysteine-rich protein that can 
occur in at least four forms due to alternative splicing of its 
mRNA. VEGF is a high-affinity ligand for Fltl and Flk1. A 
closely related member of the VEGF family is placental 40 
growth factor (PlGF), which has 47% amino acid identity 
with VEGF. PlGF also occurs in two alternatively spliced 
forms which differ in the presence or absence of a basic 
heparin binding domain of21 amino acids. 
In another embodiment, the compound includes a purified 
antibody or antigen-binding fragment that specifically binds 
the agent. 
In yet another embodiment, the expression of the agent is 
regulated by an inducible excision system. In one aspect, the 
inducible excision system is ere-lox or FLP/FRT excision 
system. In general, excision is facilitated by the introduction 
of exogenous CRE recombinase. 
In some aspects, the compound is administered via a topi-
cal, intravitreal, transcleral, periocular, conjunctival, sub-
tenon, intracameral, subretinal, subconjunctival, retrobulbar, 
suprachoriodal, intravenous, oral or intracanalicular route. In 
other aspects, the compound is included in a composition, 
Various natural and synthetic mechanisms exist for modu- 45 
lating growth factor activity including those that regulate the 
availability of agents that interact with growth factors in situ 
and in vivo. Accordingly, additional compounds, composi-
tions and methods for regulating growth factor-agent interac-
tions are desirable. 50 such as a pharmaceutically acceptable composition, which 
facilitates administration of the compound to a subject. 
SUMMARY 
Provided herein are compounds, compositions and meth-
ods for modulating angiogenesis in a target tissue. More 
specifically, provided herein are compounds, compositions 
and methods for modulating the bioavailability and activity of 
growth factors such as VEGF and/or PlGF. Such compounds, 
compositions and methods effectively modulate growth fac-
tor activity by regulating growth factor interactions with 
growth factor inactivating agents. Such agents generally 
regulate growth factor activity by sequestering the growth 
factor in a complex that inhibits growth factor growth-pro-
moting activities. Also provided are methods for identifying 
compounds that modulate growth factor sequestration. 
Accordingly, in various embodiments, methods of treating 
or preventing a condition associated with decreased vascular-
In another embodiment, a short interfering nucleic acid 
(siNA) molecule that promotes VEGF bioavailability by 
down-regulating the expression of a polypeptide encoded by 
55 the fms-like tyrosine kinase (Flt-1) gene. Exemplary 
polypeptides include isoforms such as sflt-1 and mbflt-1. 
In one aspect, the siNA molecule includes a sense region 
and an antisense region. The antisense region includes a 
sequence complementary to a sequence encoded by the fms-
60 like tyrosine kinase (Flt-1) gene and the sense region includes 
a sequence complementary to the antisense region. A siNA 
molecule is assembled from two nucleic acid fragments--one 
fragment includes the sense region and the second fragment 
includes the antisense region of the siNA molecule. In some 
65 aspects, the sense region and the antisense region are 
covalently connected via a linker molecule, such as a poly-
nucleotide linker or a non-nucleotide linker. 
US 9,198,981 B2 
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In another aspect, the siNA molecule is RNA, such as 
shRNA, siRNA and/or miRNA. In various other aspects, the 
siNA molecule includes a sequence selected from: a) a 
sequence comprising any one of SEQ ID NOs.: 1, 2, 3, 4, 5, 6, 
or 7, and having a length of 21 to 50 nucleotides; b) a 5 
sequence consisting of any one of SEQ ID NOs.: 1, 2, 3, 4, 5, 
6, or 7; or c) a sequence comprising a region of at least 19 
contiguous nucleotides having at least 90% sequence 
complementarity to, or at least 90% sequence identity with, 
anyoneofSEQIDN0:1, 2, 3, 4, 5, 6, or7, andhavingalength 10 
of 21 to 50 nucleotides. In another aspect, a cell including a 
siNA molecule of the invention is provided. 
In another embodiment, a vector that includes a nucleic 
acid sequence encoding at least one siNA molecule of the 
invention in a marmer that allows expression of the nucleic 15 
acid molecule is provided. In one aspect, the vector is 
included in a cell, such as a mammalian cell. 
In another embodiment, a siNA molecule of the invention 
is linked to cell-penetrating peptide such as penetratin, trans-
portan, pis!, TAT, pVEC, MTS, and MAP. In one aspect, the 20 
cell penetrating peptide is linked to the 5' end of the siNA 
molecule by a covalent bond. 
4 
unique carboxyl terminus of sflt-1 specific antibody reveal 
that mouse cornea (1) contains primarily sflt-1 ( 60 kDa) while 
conjunctiva (2) contains primarily mbflt-1 (190 kDa). 
FIG. 1, panel H depicts western blot analysis of two inde-
pendent mouse cornea samples immunoprecipitated with 
anti-VEGF-A antibody and immunoblotted with a biotiny-
lated antibody against the amino (N)-terminus of flt-1 that 
recognizes bothmbflt-1 and sflt-1 reveals that VEGF -A inter-
acts with sflt-1 (60 kDa). Subsequent immunoblot with a 
biotinylated anti-VEGF-A antibody confirms the pull-down 
ofVEGF-A by the immunoprecipitating antibody. 
FIG. 2, panel A depicts topical enzymatically active Cre 
recombinase abolishes corneal avascularity in flt-1 1oxP!loxP 
mice. NLS-Cre induces Cre expression (brown) in the cornea 
within 1 hour of eye drop application as demonstrated by 
immunolocalization in cell nuclei. 
FIG. 2, panel B shows that NLS-~-galactosidase expres-
sion fails to induce Cre expression (brown) in cornea within 1 
hour of eye drop application as demonstrated by immunolo-
calization in cell nuclei stained red. 
FIG. 2, panel C depicts a reducing western blot of Cre 
expression. 
In other embodiments, siRNA molecules provided herein 
are included in a composition, such as a pharmaceutically 
acceptable carrier. 
FIG. 2, panel D depicts Xgal staining of corneal flat mount 
of ROSA26R lacZ reporter mouse confirms expression of 
25 ~-galactosidase (blue) 2 days after Cre expression. 
FIG. 2, panel E depicts representative corneal flat mounts 
showing CD31+ (green) LYVE-1- blood vessels in flt-
11oxP!loxP mouse corneas 14 days after treatment with NLS-
Cre eye drops. 
FIG. 2, panel F depicts representative corneal flat mounts 
showing CD31+ (green) LYVE-1 blood vessels in flt-
11oxP!loxP mouse corneas 14 days after treatment with NLS-
~-galactosidase expression. 
In yet another embodiment, a method of identifYing a 
compound that regulates the bioavailability or biological 
activity ofVEGF in vivo or in situ, is provide. The method 
includes a) contacting corneal tissue with a test compound 
that regulates, or is believed to regulate: i) the expression of a 30 
VEGF inactivating agent; or ii) the ability of the VEGF inac-
tivating agent to bind to VEGF; b) measuring the bioavail-
ability or biological activity of VEGF; and c) identifYing a 
compound that regulates the bioavailability or biological 
activity ofVEGF. 
FIG. 2, panel G depicts the absence of corneal vasculariza-
35 tion in wild-type mice after topical application ofNLS-Cre. 
The details of one or more embodiments of the disclosure 
are set forth in the accompanying drawings and the descrip-
tion below. Other features, objects, and advantages will be 
apparent from the description and drawings, and from the 
claims. 
BRIEF DESCRIPTION OF DRAWINGS 
This patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee. 
FIG. 1, panel A is a photo of a human eye demonstrating 
abrupt termination of blood vessels in the conjunctiva (CJ) at 
its border with the cornea (C), the limbus (*). 
FIG. 1, panel B depicts a non-reducing western blot of 
mouse cornea revealing immunoreactive bands ofVEGF -A at 
100-130 kDa corresponding to bound forms and negligible 
immunoreactivity at 45-50 kDa corresponding to the free 
form. 
FIG.1, panel C depicts sflt-1 (lane 1) and VEGF-A (lane 3) 
transcripts in mouse cornea identified by representative RT-
PCR. Lane 2 is water (template negative) control. 
FIG. 1, panel D and panel E depict sflt-1 mRNA detected 
FIG. 2, panel H depicts the absence of corneal vasculariza-
tion in wild-type mice after topical application of NLS-~­
galactosidase. 
FIG. 2, panel I depicts a western blot indicating that topical 
40 application ofNLS-Cre leads to Cre expression in the mouse 
cornea and is enhanced by the prior topical application of 
proparacaine eye drops ( + P) compared to no prior application 
(-P). 
FIG. 3, panel A is a bar graph indicating that sflt -1 mRNA 
45 knockdown abolishes corneal avascularity. Real time RT-
PCR reveals reduced sflt-1 mRNA in wild-type mouse cor-
neas 3 days after injection of pshRNA-sflt-1 but not pshRNA-
mbflt-1. * P<0.05, Bonferroni corrected Marm Whitney U 
50 
55 
test. Error bars depict s.e.m. 
FIG. 3, panel B is a bar graph depicting data generated from 
an ELISA. The data indicates that sflt-1 protein is reduced in 
wild-type mouse corneas 3 days after injection of pshRNA-
sflt-1 but not pshRNA-mbflt-1. * P<0.05, Bonferroni cor-
rected Maun Whitney U test. Error bars depict s.e.m. 
FIG. 3, panel C is a bar graph depicting data generated from 
an ELISA. The data indicates that free VEGF-A protein is 
increased in wild-type mouse corneas 3 days after injection of 
pshRNA-sflt-1 but not pshRNA-mbflt-1. * P<0.05, Bonfer-
roni corrected Mann Whitney U test. Error bars depict s.e.m. 
FIG. 3, panel D provides an image of an eye expressing 
pshRNA-sflt-1. 
by in situ hybridization in mouse corneal epithelium ( epi) and 60 
stroma (str). Antisense RNA probes show purple-brown reac-
tivity. Sense RNA probes show negligible reactivity. FIG. 3, panel E depicts a corneal flat mount showing 
CD31 +(green) LYVE-1- blood vessels at 14 days after injec-
tion. pshRNA-sflt-1 expression induces CV in wild-type 
65 mice. Scale bars are 500 f.tm. 
FIG. 1, panel F depicts immunolocalization (brown) of 
sflt-1 protein in mouse cornea. 
FIG. 1, panel G depicts reducing western blots using an 
antibody against the amino (N)-terminus of flt-1 that recog-
nizes both mbflt-1 and sflt-1 and an antibody against the 
FIG. 3, panel F depicts a corneal flat mount showing 
CD31 +(green) LYVE-1- blood vessels at 14 days after injec-
US 9,198,981 B2 
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tion. pshRNA-mbflt-1 expression fails to induce CV in wild-
type mice. Scale bars are 500 f.tm. 
FIG. 3, panel G is a graph depicting a decrease in sflt-1 
(sVEGFRl) expression by a siRNA sequence that targets 
sflt-1 (sVEGFRl). 
FIG. 3, panel H depicts suppression of unique tail of sFLT 
by siRNA targeting unique tail. 
FIG. 3, panel I depicts suppression of mRNA of VEGF 
binding domains (553 bp) of sFLT by siRNA targeting unique 
tail, while 18sRNA (315 bp) is unaffected. 10 
6 
cornea, retina, and RPE/choroid; 3) VIT injection leads to 
expression in lens, retina, and RPE/choroid; and 4) SR injec-
tion leads to expression in retina and RPE/choroid over 24 
hrs. 
Like reference symbols in the various drawings indicate 
like elements. 
DETAILED DESCRIPTION 
Before describing the invention in detail, it is to be under-
stood that this invention is not limited to particular composi-
tions or biological systems, which can, of course, vary. It is 
also to be understood that the terminology used herein is for 
the purpose of describing particular embodiments only, and is 
FIG. 3, panel J depicts western blot analysis of VEGF 
expression (band visible at 25 kD) in mouse corneas using 
immunoprecipitation by antibody to sFLT unique tail and 
demonstrating that siRNA knock down of sflt-1 expression 
frees VEGF from sflt-1 sequestration. 
FIG. 4, panel A provides reducing western blots showing a 
deficiency of sflt-1 in corneas of corn! and Pax6+1- mice 
compared to background strain A/J and Pax6+1+ mice. 
15 not intended to be limiting. As used in this specification and 
the appended claims, the singular forms "a," "an," and "the" 
include plural referents unless the content clearly dictates 
otherwise. Unless defined otherwise, all technical and scien-
FIG. 4, panel B is a bar graph showing that sflt-1/Fc admin-
istration inhibits CV in corn! and Pax6+1- mice compared to 20 
IgGl/Fc (by 87±2% in corn!; P=O.Ol; by 85±3% inPax6+1-; 
P=0.03) and to control untreated mice (by 87±2% in corn!; 
P=O.Ol; by 84±3% in Pax6+1-; P=0.03). Significance by Bon-
ferroni corrected Mann Whitney U test. Error bars depict 
s.e.m. 25 
FIG. 4, panel C depicts flat mounts showing CD31 +(green) 
LYVE-1-corneal blood vessels. 
FIG. 4, panel D depicts immunostaining of a cornea and 
revealing a deficiency of sflt-1 (brown) in cornea with aniri-
dia-associated vascularization (top), revealed by vascular cell 30 
adhesion molecule-! (VCAM-1) staining (red) compared to 
the avascular cornea (lack ofVCAM -1 staining) of a different 
cornea without aniridia (bottom). 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
invention pertains. Although any methods and materials simi-
lar or equivalent to those described herein can be used in the 
practice for testing of the invention( s ), specific examples of 
appropriate materials and methods are described herein. 
As will be described in more detail below, the invention is 
based, at least in part, on compounds, compositions and meth-
ods for regulating angiogenesis in a target tissue. More spe-
cifically, provided herein are compounds, compositions and 
methods for modulating the bioavailability and activity of 
VEGF or PlGF. Such compounds, compositions and methods 
effectively modulate VEGF or PlGF activity by regulating 
VEGF or PlGF interactions with VEGF or PlGF inactivating 
agents. Such agents generally regulate VEGF or PlGF activity 
by sequestering VEGF or PlGF in a complex that inhibits FIG. 4, panel E depicts a marked deficiency of sflt-1 (red-
dish brown) staining in cornea of Antillean manatee. 35 VEGF or PlGF vascularization-promoting activities. 
FIG. 4, panel F depicts the presence of sflt-1 (reddish 
brown) staining in cornea of a dugong. 
FIG. 4, panel G depicts the presence of sflt-1 (reddish 
brown) staining in cornea of an African elephant. 
FIG. 4, panel H depicts the presence of sflt-1 (reddish 40 
brown) staining in cornea of a beaked whale. 
FIG. 4, panel I depicts reducing western blots using an 
antibody against the amino (N) terminus offlt-1 reveal pres-
ence of sflt-1 (60 kDa) and absence ofmbflt-1 (190 kDa) in 
corneas of bottlenose dolphin (1) and Asian elephant (2). 45 
Scale bars are 200 flill· 
FIG. 5 depicts a reducing western blot of Cre expression 
showing that 1) AC injection of NLS-Cre leads to corneal 
expression of Cre; 2) SC injection leads to expression in the 
cornea, retina, and RPE/choroid; 3) VIT injection leads to 50 
expression in lens, retina, and RPE/choroid; and 4) SR injec-
tion leads to expression in retina and RPE/choroid over 1 hr. 
FIG. 6 depicts a reducing western blot of Cre expression 
showing that 1) AC injection of NLS-Cre leads to corneal 
expression of Cre; 2) SC injection leads to expression in the 55 
cornea, retina, and RPE/choroid; 3) VIT injection leads to 
expression in lens, retina, and RPE/choroid; and 4) SR injec-
tion leads to expression in retina and RPE/choroid over 3 hrs. 
FIG. 7 depicts a reducing western blot of Cre expression 
showing that 1) AC injection of NLS-Cre leads to corneal 60 
expression of Cre; 2) SC injection leads to expression in the 
cornea, retina, and RPE/choroid; 3) VIT injection leads to 
expression in lens, retina, and RPE/choroid; and 4) SR injec-
tion leads to expression in retina and RPE/choroid over 8 hrs. 
FIG. 8 depicts a reducing western blot of Cre expression 65 
showing that 1) AC injection of NLS-Cre leads to corneal 
expression of Cre; 2) SC injection leads to expression in the 
Accordingly, in various embodiments, methods of treating 
or preventing a condition associated with decreased vascular-
ity in a subject, are provided. The methods include adminis-
tering to the subject a compound that regulates the bioavail-
ability or biological activity ofVEGF or PlGF by modulating 
the availability of a VEGF or PLGF inactivating agent. The 
administering is sufficient to treat or prevent the condition in 
the subject. An inactivating agent, as described herein, can 
form a complex with VEGF or PlGF by binding to VEGF or 
PlGF. A compound provided herein can modulate VEGF or 
PlGF bioavailability or biological activity by preventing, 
inhibiting or disrupting the formation of the complex. In one 
aspect, this is accomplished by decreasing the amount of the 
agent, such as by reducing or inhibiting the expression of the 
agent. By "reduce or inhibit" is meant the ability to cause an 
overall decrease of 20% or greater, more preferably of 40%, 
50%, 60%, 70%, 80%, and 90% or greater change in the level 
of the agent. By "expression" is meant the detection of a gene 
or polypeptide by standard art known methods. For example, 
polypeptide expression is often detected by western blotting, 
DNA expression is often detected by Southern blotting or 
polymerase chain reaction (PCR), and RNA expression is 
often detected by northern blotting, PCR, or RNAse protec-
tion assays. 
By "gene", or "target gene" or "target DNA", is meant a 
nucleic acid that encodes an RNA, for example, nucleic acid 
sequences including, but not limited to, structural genes 
encoding a polypeptide. A gene or target gene can also encode 
a functional RNA (fRNA) or non-coding RNA (ncRNA), 
such as small temporal RNA (stRNA), micro RNA (miRNA), 
small nuclear RNA (snRNA), short interfering RNA 
(siRNA), small nucleolar RNA (snRNA), ribosomal RNA 
US 9,198,981 B2 
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(rRNA), transfer RNA (tRNA) and precursor RNAs thereof. 
Such non-coding RNAs can serve as target nucleic acid mol-
ecules for siNA mediated RNA interference in modulating 
the activity of FRNA or ncRNA involved in functional or 
regulatory cellular processes. Abberant fRNA or ncRNA 
activity leading to disease can therefore be modulated by 
siNA molecules of the invention. siNA molecules targeting 
fRNA and ncRNA can also be used to manipulate or alter the 
genotype or phenotype of a subject, organism or cell, by 
intervening in cellular processes such as genetic imprinting, 
transcription, translation, or nucleic acid processing (e.g., 
transamination, methylation etc.). 
By "compound" is meant any small molecule chemical 
compound, antibody, nucleic acid molecule, or polypeptide, 
or fragments thereof. Compounds particularly useful for the 
compositions and methods of the invention can alter, prefer-
ably increase, the bioavailability or biological activity of 
VEGF or PlGF by at least 10%, 20%, 30%, 40%, 50%, 60%, 
70%, 80%, 90% or more. Accordingly, the compounds, com-
positions and methods provided herein can be used to treat 
conditions associated with decreased vascularity. For 
example, tissue that requires vascularization, neovasculariza-
tion and/or revascularization of in a subject can be treated by 
a compound, composition or method provided herein. Such 
conditions are described in more detail below and include 
ocular disorders, preeclampsia, cerebrovascular disorders, 
cardiovascular disorders, and wound healing disorders, or 
any proliferative, inflammatory or neurologic disorder that 
can be successfully treated or prevented by increasing the 
bioavailability or biological activity of a growth factor. 
Accordingly, in one embodiment, compounds provided 
herein include nucleobase oligomers that regulate the expres-
sion of a target nucleic acid sequence encoding an inactivat-
ing agent. By "nucleobase oligomer" is meant an oligomer, 
regardless of length, that is complementary to the coding 
strand or mRNA of any nucleic acid sequence encoding an 
inactivating agent. A nucleobase oligomer generally includes 
a chain of at least eight, twelve, or at least sixteen nucleo-
bases, joined together by linkage groups. Included in this 
definition are natural and non-natural oligonucleotides, both 
modified and unmodified, as well as oligonucleotide mimet-
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chain alkyl or cycloalkyl intersugar linkages or short chain 
heteroatomic or heterocyclic intersugar linkages. In other 
embodiments, such as the protein-nucleic acid (PNA) back-
bone, the phosphodiester backbone of the oligonucleotide 
may be replaced with a polyamide backbone, the bases being 
bound directly or indirectly to the aza nitrogen atoms of the 
polyamide backbone (Nielsen et a!., Science 254:1497 
(1991)). Other preferred oligonucleotides may contain alkyl 
and halogen-substituted sugar moieties. Oligonucleotides 
10 may also have sugar mimetics such as cyclobutyls in place of 
the pentofuranosyl group. Other embodiments may include at 
least one modified base form. Some specific examples of such 
modified bases include 2-(amino)adenine, 2-(methylamino) 
adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalklyamino) 
15 adenine, or other heterosubstituted alkyladenines. Each of the 
above is referred to as a "modification" herein. 
As previously noted, a nucleobase oligomer includes small 
nucleic acid molecules useful for RNA interference (RNAi), 
such as short interfering nucleic acid (siNA), short interfering 
20 RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA 
(miRNA), and short hairpin RNA (shRNA) molecules 
capable of mediating or that mediate RNA interference 
(RNAi) against the expression ofVEGF or PlGF inactivating 
agents, such as polypeptide encoded by the fms-like tyrosine 
25 kinase (Flt-1) gene. Such small nucleic acid molecules are 
useful, for example, in providing compositions for treatment 
of traits, diseases and conditions that can respond to modu-
lation of VEGF or PlGF activity in a subject or organism. 
Such proliferative diseases and conditions include ocular dis-
30 eases and conditions, dermatological diseases and condi-
tions, and any other disease, condition, trait or indication that 
can respond to the level ofVEGF activity in a cell or tissue. 
Accordingly, nucleobase oligomers provided herein 
include short interfering nucleic acid (siNA) molecules. The 
35 term "short interfering nucleic acid", "siNA", "short interfer-
ing RNA", "siRNA", "short interfering nucleic acid mol-
ecule", "short interfering oligonucleotide molecule", or 
"chemically-modified short interfering nucleic acid mol-
ecule" as used herein refers to any nucleic acid molecule 
40 capable of inhibiting or down regulating expression of an 
inactivating agent by mediating RNA interference "RNAi" or 
gene silencing in a sequence-specific marmer. For example 
the siNA can be a double-stranded nucleic acid molecule 
ics such as Protein Nucleic Acids, locked nucleic acids, and 
arabinonucleic acids. Numerous nucleobases and linkage 
groups may be employed in the nucleobase oligomers of the 
invention, including those described in U.S. patent Publica- 45 
tion Nos. 20030114412 (see for example paragraphs 27-45 of 
the publication) and 20030114407 (see for example para-
graphs 35-52 of the publication), incorporated herein by ref-
erence. The nucleobase oligomer can also be targeted to the 
translational start and stop sites. 
comprising self-complementary sense and antisense regions, 
wherein the antisense region comprises nucleotide sequence 
that is complementary to nucleotide sequence in a target 
nucleic acid molecule or a portion thereof and the sense 
region having nucleotide sequence corresponding to the tar-
get nucleic acid sequence or a portion thereof. The siNA can 
50 be assembled from two separate oligonucleotides, where one 
strand is the sense strand and the other is the antisense strand, 
wherein the antisense and sense strands are self-complemen-
tary (i.e., each strand comprises nucleotide sequence that is 
The term "nucleobase oligomer" includes short interfering 
nucleic acid (siNA) molecules such as dsRNA, siRNA, 
shRNA, miRNA or mimetics thereof that inhibits the expres-
sion of a target gene (see below). An inhibitory nucleobase 
oligomer typically reduces the amount of a target mRNA, or 55 
protein encoded by such mRNA, by at least 5%, more desir-
able by at least 10%, 25%, 50%, or even by 7 5%, 85%, or 90% 
relative to an untreated control. Methods for measuring both 
mRNA and protein levels are well-known in the art; exem-
plary methods are described herein. The nucleobase oligomer 60 
(or a portion thereof) may contain a modified backbone. 
Phosphorothioate, phosphorodithioate, and other modified 
backbones are known in the art. The nucleobase oligomer 
may also contain one or more non-natural linkages. 
Specific examples of some modified nucleic acids or 65 
nucleobases envisioned for this invention may contain phos-
phorothioates, phosphotriesters, methyl phosphonates, short 
complementary to nucleotide sequence in the other strand; 
such as where the antisense strand and sense strand form a 
duplex or double stranded structure, for example wherein the 
double stranded region is about 15 to about 30, e.g., about 15, 
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29 or 30 base 
pairs; the antisense strand comprises nucleotide sequence that 
is complementary to nucleotide sequence in a target nucleic 
acid molecule or a portion thereof and the sense strand com-
prises nucleotide sequence corresponding to the target 
nucleic acid sequence or a portion thereof (e.g., about 15 to 
about 25 or more nucleotides of the siNA molecule are 
complementary to the target nucleic acid or a portion thereof). 
Alternatively, the siNA is assembled from a single oligo-
nucleotide, where the self-complementary sense and anti-
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sense regions of the siNA are linked by means of a nucleic 
acid based or non-nucleic acid-based linker(s ). The siNA can 
be a polynucleotide with a duplex, asymmetric duplex, hair-
pin or asymmetric hairpin secondary structure, having self-
complementary sense and antisense regions, wherein the anti-
sense region comprises nucleotide sequence that is 
complementary to nucleotide sequence in a separate target 
nucleic acid molecule or a portion thereof and the sense 
region having nucleotide sequence corresponding to the tar-
get nucleic acid sequence or a portion thereof. The siNA can 10 
be a circular single-stranded polynucleotide having two or 
more loop structures and a stem comprising self-complemen-
tary sense and antisense regions, wherein the antisense region 
comprises nucleotide sequence that is complementary to 
nucleotide sequence in a target nucleic acid molecule or a 15 
portion thereof and the sense region having nucleotide 
sequence corresponding to the target nucleic acid sequence or 
a portion thereof, and wherein the circular polynucleotide can 
be processed either in vivo or in vitro to generate an active 
siNA molecule capable of mediating RNAi. The siNA can 20 
also comprise a single stranded polynucleotide having nucle-
otide sequence complementary to nucleotide sequence in a 
target nucleic acid molecule or a portion thereof (for example, 
where such siNA molecule does not require the presence 
within the siNA molecule of nucleotide sequence corre- 25 
sponding to the target nucleic acid sequence or a portion 
thereof), wherein the single stranded polynucleotide can fur-
ther comprise a terminal phosphate group, such as a 5'-phos-
phate, or 5',3'-diphosphate. 
In some embodiments, the siNA molecule of the invention 30 
comprises separate sense and antisense sequences or regions, 
wherein the sense and antisense regions are covalently linked 
by nucleotide or non-nucleotide linkers molecules as is 
known in the art, or are alternately non-covalently linked by 
ionic interactions, hydrogen bonding, van der waals interac- 35 
tions, hydrophobic interactions, and/or stacking interactions. 
In certain embodiments, the siN A molecules of the invention 
comprise nucleotide sequence that is complementary to 
nucleotide sequence of a target gene. In another embodiment, 
the siN A molecule of the invention interacts with nucleotide 40 
10 
nucleic acid, short interfering modified oligonucleotide, 
chemically-modified siRNA, post-transcriptional gene 
silencing RNA (ptgsRNA), and others. Short hairpin interfer-
ing RNA (shRNA) is a single molecule (e.g., a single oligo-
nucleotide chain) that comprises both the sense and antisense 
strands of an interfering RNA in a stem-loop or hairpin struc-
ture (e.g., a shRNA). For example, shRNAs can be expressed 
from DNA vectors in which the DNA oligonucleotides 
encoding a sense interfering RNA strand are linked to the 
DNA oligonucleotides encoding the reverse complementary 
antisense interfering RNA strand by a short spacer. If needed 
for the chosen expression vector, 3' terminal T's and nucle-
otides forming restriction sites may be added. The resulting 
RNA transcript folds back onto itself to form a stem-loop 
structure. 
Each sequence of a siNA molecule of the invention is 
independently about 15 to about 30 nucleotides in length, in 
specific embodiments about 15, 16, 17, 18, 19, 20, 21, 22, 23, 
24, 25, 26, 27, 28, 29, or 30 nucleotides in length. In another 
embodiment, the siNA duplexes of the invention indepen-
dently comprise about 15 to about 30 base pairs (e.g., about 
15, 16, 17, 18, 19,20,21,22,23,24,25,26,27,28,29,or30). 
One or more strands of the siNA molecule of the invention 
independently comprises about 15 to about 30 nucleotides 
(e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 
29, or 30) that are complementary to a target nucleic acid 
molecule. siNA molecules of the invention comprising hair-
pin or circular structures are about 35 to about 55 (e.g., about 
35, 40, 45, 50 or 55) nucleotides in length, or about 38 to about 
44 (e.g., about 38, 39, 40, 41, 42, 43, or 44) nucleotides in 
length and comprising about 15 to about 25 (e.g., about 15, 
16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) base pairs. 
siNA molecules provided herein include those that having 
a sequence of any one of SEQ ID NOs.: 1, 2, 3, 4, 5, 6, or 7. 
Such molecules include those that consist of any one of SEQ 
ID NOs.:1, 2, 3, 4, 5, 6, or 7. In addition, siNA molecules 
provided herein include those having a region of at least 19 
contiguous nucleotides having at least 90% sequence 
complementarity to, or at least 90% sequence identity with, 
any one of SEQ ID N0:1, 2, 3, 4, 5, 6, or 7. "Sequence 
identity" herein means the extent to which two nucleotide 
sequences are invariant. "Sequence alignment" means the 
process oflining up two or more sequences to achieve maxi-
mallevels of identity for the purpose of assessing the degree 
sequence of a target gene in a manner that causes inhibition of 
expression of the target gene. As used herein, siNA molecules 
need not be limited to those molecules containing only RNA, 
but further encompasses chemically-modified nucleotides 
and non-nucleotides. In certain embodiments, the short inter-
fering nucleic acid molecules of the invention lack 2'-hydroxy 
(2'-0H) containing nucleotides. Applicant describes in cer-
tain embodiments short interfering nucleic acids that do not 
require the presence of nucleotides having a 2'-hydroxy group 
for mediating RNAi and as such, short interfering nucleic acid 
molecules of the invention optionally do not include any 
ribonucleotides (e.g., nucleotides having a 2'-0H group). 
Such siNA molecules that do not require the presence of 
ribonucleotides within the siNA molecule to support RNAi 
can however have an attached linker or linkers or other 
attached or associated groups, moieties, or chains containing 
one or more nucleotides with 2'-0H groups. Optionally, siNA 
molecules can comprise ribonucleotides at about 5, 10, 20, 
30, 40, or 50% of the nucleotide positions. The modified short 
interfering nucleic acid molecules of the invention can also be 
referred to as short interfering modified oligonucleotides 
"siMON." As used herein, the term siNA is meant to be 
equivalent to other terms used to describe nucleic acid mol-
ecules that are capable of mediating sequence specific RNAi, 
for example short interfering RNA (siRNA), double-stranded 
RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA 
(shRNA), short interfering oligonucleotide, short interfering 
45 of similarity. Numerous methods for aligning sequences and 
assessing similarity/identity are known in the art such as, for 
example, the Cluster Method, wherein similarity is based on 
the MEGALIGN algorithm, as well as BLASTN, BLASTP, 
and PASTA (Lipman and Pearson, 1985; Pearson and Lip-
50 man, 1988). When using all of these programs, the preferred 
settings are those that results in the highest sequence similar-
ity. 
By "RNA interference" or "RNAi" is meant a biological 
process of inhibiting or down regulating gene expression in a 
55 cell as is generally known in the art and which is mediated by 
short interfering nucleic acid molecules, see for example 
Zamore and Haley, Science, 309: 1519; Vaughn and Marti ens-
sen, Science, 309: 1525; and Kreutzer et a!., International 
PCT Publication No. WO 00/44895; Zernicka-Goetz eta!., 
60 International PCT Publication No. WO 01/36646; Fire, Inter-
national PCT Publication No. WO 99/32619; Plaetinck eta!., 
International PCT Publication No. WO 00/01846; Mello and 
Fire, International PCT Publication No. WO 01/29058; Des-
champs-Depaillette, International PCT Publication No. WO 
65 99/07409; and Li et a!., International PCT Publication No. 
WO 00/44914). In addition, as used herein, the term RNAi is 
meant to be equivalent to other terms used to describe 
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sequence specific RNA interference, such as post transcrip-
tional gene silencing, translational inhibition, transcriptional 
inhibition, or epigenetics. For example, siNA molecules of 
the invention can be used to epigenetically silence genes at 
both the post-transcriptional level or the pre-transcriptional 
level. In a non-limiting example, epigenetic modulation of 
gene expression by siNA molecules of the invention can 
result from siNA mediated modification of chromatin struc-
ture or methylation patterns to alter gene expression. In 
another non-limiting example, modulation of gene expres-
sion by siN A molecules of the invention can result from siNA 
mediated cleavage of RNA (either coding or non-coding 
RNA) via RISC, or alternately, translational inhibition as is 
known in the art. In another embodiment, modulation of gene 
expression by siNA molecules of the invention can result 
from transcriptional inhibition (see for example Janowski et 
a!., 2005, Nature Chemical Biology, 1:216). 
RNA interference (RNAi) is a process by which double-
stranded RNA (dsRNA) is used to silence gene expression. 
While not wanting to be bound by theory, RNAi begins with 
the cleavage of longer dsRNAs into small interfering RNAs 
(siRNAs) by an RNaseiii-like enzyme, dicer. SiRNAs are 
dsRNAs that are usually about 19 to 28 nucleotides, or 20 to 
12 
expressly incorporated herein by reference. The cell-pen-
etrating pep tides of the present invention preferably include, 
but are not limited to, penetratin, transportan, pis!, TAT( 48-
60), pVEC, MTS, and MAP. 
Penetratin is a 16-amino-acid polypeptide derived from the 
third alpha-helix of the homeodomain of Drosophila anten-
napedia. Its structure and function have been well studied and 
characterized: Derossi et a!., Trends Cell Bioi., 8:84-87, 
1998; Dunican eta!., Biopolymers, 60:45-60, 2001; Hall-
10 brink et a!., Biochim. Biophys. Acta, 1515:101-09, 2001; 
Bolton eta!., Eur. J. Neurosci., 12:2847-55, 2000; Kilk eta!., 
Bioconjug. Chern., 12:911-16, 2001; Bellet-Amalric eta!., 
Biochim. Biophys.Acta, 1467:131-43, 2000; Fischer eta!., J. 
Pept. Res., 55: 163-72, 2000; Thoren et a!., FEBS Lett., 
15 482:265-68, 2000. 
As previously noted, a compound provided herein modu-
lates the ability of an inactivating agent to form a complex 
with VEGF or PIGF by binding to VEGF or PIG F. An "inac-
tivating agent," as used herein includes any polypeptide 
20 encoded by the fms-like tyrosine kinase (Flt-1) gene. Exem-
plary polypeptides include isoforms such as sflt-1 and mbflt-
1. 
25 nucleotides, or 21 to 22 nucleotides in length and often 
contain 2-nucleotide 3' overhangs, and 5' phosphate and 3' 25 
hydroxyl termini. One strand of the siRNA is incorporated 
into a ribonucleoprotein complex known as the RNA-induced 
silencing complex (RISC). RISC uses this siRNA strand to 
identify mRNA molecules that are at least partially comple-
mentary to the incorporated siRNA strand, and then cleaves 30 
these target mRNAs or inhibits their translation. Therefore, 
the siRNA strand that is incorporated into RISC is known as 
the guide strand or the antisense strand. The other siRNA 
strand, known as the passenger strand or the sense strand, is 
eliminated from the siRNA and is at least partially homolo- 35 
gous to the target mRNA. Those of skill in the art will recog-
nize that, in principle, either strand of an siRNA can be 
incorporated into RISC and function as a guide strand. How-
ever, siRNA design (e.g., decreased siRNA duplex stability at 
the 5' end of the antisense strand) can favor incorporation of 40 
the antisense strand into RISC. 
In another embodiment, a compound provided herein 
includes antibodies that prevent, inhibit or disrupt the forma-
tion of a growth factor-inactivating agent complex by specifi-
cally binding to the inactivating agent. Such neutralizing 
antibodies include polyclonal as well as monoclonal antibod-
ies. The production and identification of antibodies that bind 
to a target molecule is well known in the art. By "specifically 
binds" is meant a compound or antibody which recognizes 
and binds the inactivating agent but that does not substantially 
recognize and bind other molecules in a sample, for example, 
a biological sample, which naturally includes a polypeptide 
of the invention. 
Also included are humanized antibodies. By "humanized 
antibody" is meant an immunoglobulin amino acid sequence 
variant or fragment thereof that is capable of binding to a 
predetermined antigen. Ordinarily, the antibody will contain 
both the light chain as well as at least the variable domain of 
a heavy chain. The antibody also may include the CHI, hinge, 
CH2, CH3, or CH4 regions of the heavy chain. The human-
Interfering RNA of embodiments of the invention appear to 
act in a catalytic manner for cleavage of target mRNA, i.e., 
interfering RNA is able to effect inhibition of inactivating 
agent expression in substoichiometric amounts. As compared 
to antisense therapies, significantly less interfering RNA is 
required to provide a therapeutic effect under such cleavage 
conditions. siNA molecules of the invention include duplex 
forming oligonucleotides "DFOs", (see for example Vaish et 
a!., U.S. Ser. No. 10/727,780 filed Dec. 3, 2003 and Interna-
tional PCT Application No. US04/16390, filed May 24, 
2004). 
In some embodiments, an siNA molecule provided herein 
can be functionally associated with a cell-penetrating pep-
tide." As used herein, a "cell-penetrating peptide" is a peptide 
that comprises a short (about 12-30 residues) amino acid 
sequence or functional motif that confers the energy-indepen-
dent (i.e., non-endocytotic) translocation properties associ-
ated with transport of the membrane-permeable complex 
across the plasma and/or nuclear membranes of a cell. The 
cell-penetrating peptide used in the membrane-permeable 
complex of the present invention preferably comprises at 
least one non-functional cysteine residue, which is either free 
or derivatized to form a disulfide link with a double-stranded 
ribonucleic acid that has been modified for such linkage. 
Representative amino acid motifs conferring such properties 
are listed in U.S. Pat. No. 6,348,185, the contents of which are 
ized antibody comprises a framework region (FR) having 
substantially the amino acid sequence of a human immuno-
globulin and a complementarity determining region (CDR) 
45 having substantially the amino acid sequence of a non-human 
immunoglobulin (the "import" sequences). 
Generally, a humanized antibody has one or more amino 
acid residues introduced into it from a source that is non-
human. In general, the humanized antibody will comprise 
50 substantially all of at least one, and typically two, variable 
domains (Fab, Fab', F(ab').sub.2, Fabc, Fv) in which all or 
substantially all of the CDR regions correspond to those of a 
non-human immunoglobulin and all or substantially all of the 
FR regions are those of a human immunoglobulin consensus 
55 sequence. The humanized antibody optimally will comprise 
at least a portion of an immunoglobulin constant region (Fe), 
typically that of a human immunoglobulin. By "complemen-
tarily determining region (CDR)" is meant the three hyper-
variable sequences in the variable regions within each of the 
60 immunoglobulin light and heavy chains. By "framework 
region (FR)" is meant the sequences of amino acids located 
on either side of the three hypervariable sequences (CDR) of 
the immunoglobulin light and heavy chains. 
The FR and CDR regions of the humanized antibody need 
65 not correspond precisely to the parental sequences, e.g., the 
import CDR or the consensus FR may be mutagenized by 
substitution, insertion or deletion of at least one residue so 
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that the CDR or FR residue at that site does not correspond to 
either the consensus or the import antibody. Such mutations, 
however, will not be extensive. Usually, at least 75%, prefer-
ably 90%, and most preferably at least 95% of the humanized 
antibody residues will correspond to those of the parental FR 
and CDR sequences. 
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"facilitate," or "promote," but the use of the word "modulate" 
or "regulate" is not limited to these definitions. 
By "inhibit", "down-regulate", or "reduce", it is meant that 
the expression of gene encoding an inactivating agent, or level 
of RNA molecules or equivalent RNA molecules encoding 
one or more proteins or protein subunits associated with an 
inactivating agent, or activity of one or more proteins or 
protein subunits of an agent, is reduced below that observed in 
the absence of the compounds (e.g., siNA, antibodies, or gene 
In yet another embodiment, a compound of the invention 
includes compounds that facilitate the ablation of a genetic 
sequence encoding an inactivating agent. Such compounds 
include Cre recombinase (e.g., NLS-Cre) which can be used 
in methods of achieving on-demand ere-lox recombination 
for gene deletion. The data provided herein indicate that 
NLS-Cre can be injected into various different compartments 
10 ablation compounds) of the invention. In one embodiment, 
inhibition, down regulation, or reduction of gene expression 
is associated with post transcriptional silencing, such as 
RNAi mediated cleavage of a target nucleic acid molecule 
(e.g. RNA) or inhibition of translation. In one embodiment, 
of the eye to achieve spatial targeting of any gene. Further, the 
present studies demonstrate that application of topical eye 
drops ofNLS-Cre lead to ere-expression and recombination 
and gene deletion of "floxed" genes in the cornea. Accord-
ingly, methods of conditionally reducing the expression of a 
coding sequence in a target cell are provided. The term "con-
ditionally reduced expression" refers to the flexibility inher-
ent in the methods/vectors of this invention, which enable 
regulation of reducing expression of a coding sequence in a 
target cell. In one embodiment, reducing expression via the 
vectors/methods of this invention is controlled overtime, or in 25 
a cell or tissue-specific manner. 
15 inhibition, down regulation, or reduction of gene expression 
is associated with pretranscriptional silencing, such as by 
gene ablation. 
The compounds, compositions and methods decribed 
herein allow for the upregulation of growth factor protein 
20 bioavialibility or biological activity by inhibiting or down-
regulating the presence of a growth factor inactivating agent. 
By "up-regulate", or "promote", it is meant that the activity of 
one or more proteins or protein subunits, is increased above 
that observed in the absence of the nucleic acid molecules 
The ere recombinase is derived from a P1 bacteriophage 
(Abremski andHoess, J. Bioi. Chern. 259:1509, 1984) which 
acts on a specific 34 base pair DNA sequence known as 
"loxP" (locus of crossover), which is, in turn, comprised of 30 
two 13 base pair inverted repeats (serving as the recombinase 
binding sites) flanking an 8 base pair core sequence (Current 
Opinion in Biotechnology 5:521, 1994). Cre catalyzes the 
rearrangement of DNA sequences that contain loxP sites. 
Recombination between two loxP sites (catalyzed by the ere 35 
protein) causes, in certain cases, the loss of sequences flanked 
by these sites (for a review seeN. Kilby eta!, Trends Genet., 
9:413, 1993). Compounds, compositions and methods pro-
vided herein encompass the introduction of Cre recombinase 
(e.g., siNA) of the invention. In one embodiment, up-regula-
tion of growth factor bioavailability includes using a com-
pound, such as an siNA molecule, to down regulate the avail-
ability of an inactivating reagent, such as sflt-1. The down 
regulation of gene expression can, for example, be induced by 
a coding RNA or its encoded protein, such as through nega-
tive feedback or antagonistic effects. The down regulation of 
gene expression can, for example, be induced by a non-
coding RNA having regulatory control over a gene of interest, 
for example by silencing expression of the gene via transla-
tional inhibition, chromatin structure, methylation, RISC 
mediated RNA cleavage, or translational inhibition. As such, 
inhibition or down regulation of targets that down regulate, 
suppress, or inactivate a growth factor of interest can be used 
to up-regulate or promote the bioavailability of the growth 
factor of interest toward therapeutic use. 
Throughout the present specification, compounds, compo-
sitions and methods are described that are useful for modu-
lating angiogenesis an/or vasculogenesis by promoting the 
activity of growth factors associated with such processes. The 
compounds, compositions and methods generally target 
growth factor-inactivating agents such that the bioavailability 
or biological activity of a growth factor is increased. 
Angiogenesis is a process of new blood vessel develop-
ment from pre-existing vasculature. It plays an essential role 
in embryonic development, normal growth of tissues, wound 
healing, the female reproductive cycle (i.e., ovulation, men-
struation and placental development), as well as a major role 
in many diseases. One of the most important growth and 
survival factors for endothelium is vascular endothelial 
in to a cell or tissue in order to conditionally regulate the 40 
expression of a VEGF or FIGF inactivating agent by genomic 
deletion. For example, sflt-1 expression was suppressed by 
conditional Cre-lox mediated gene ablation by topical appli-
cation ofNLS-Cre and by corneal injection of plasmid encod-
ing Cre recombinase (pCre) in flt-1 1oxP!loxP mouse eyes; 45 
P<O.OOl) within 2 days. Cre expression was accompanied by 
significantly reduced sflt -1 and increased free VEGF-A. N ei-
ther plasmid induced CV in wild-type mice. To avoid injec-
tion trauma, a cell permeable enzymatically active Cre con-
taining a nuclear localization sequence (NLS-Cre) was 50 
delivered to the cornea by topical eye drops (FIG. 2, panels 
A-D). NLS-Cre, but not NLS-~-galactosidase, induced CV in 
flt-1 1oxP!loxP mouse eyes (P<O.OOl) within 2 days (FIG. 2, 
panels E and F). Neither NLS-enzyme induced CV in wild-
type mice (FIG. 2, panels G and H). 
As noted throughout the present specification, compounds 
that regulate the bioavailability or biological activity of 
VEGF or PIGF by modulating the availability of a VEGF or 
PLGF inactivating agent, are provided. By "modulate" or 
"regulate" is meant that the expression of the gene, or level of 60 
a RNA molecule or equivalent RNA molecules encoding one 
55 growth factor (VEGF). VEGF induces angiogenesis and 
endothelial-cell proliferation and plays an important role in 
regulating vasculogenesis. VEGF is a heparin-binding glyco-
protein that is secreted as a homodimer of 45 kDa. Most types 
or more proteins or protein subunits, or activity of one or more 
proteins or protein subunits is up regulated or down regulated, 
such that expression, level, or activity is greater than or less 
than that observed in the absence of the modulator or regula- 65 
tor, i.e., a compound provided herein. For example, the term 
"modulate" or "regulate" can mean "inhibit," "prevent," 
of cells, but usually not endothelial cells themselves, secrete 
VEGF. Since the initially discovered VEGF, VEGF-A, 
increases vascular permeability, it was known as vascular 
permeability factor. In addition, VEGF causes vasodilatation, 
partly through stimulation of nitric oxide synthase in endot-
helial cells. VEGF can also stimulate cell migration and 
inhibit apoptosis (see "R&D Systems, Cytokine Mini 
Reviews, Vascular Endothelial Growth Factor (VEGF)," 
Copyright 2002 R&D Systems). 
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There are several splice variants ofVEGF-A. The major 
ones include: 121, 165, 189 and 206 amino acids (aa), each 
one comprising a specific exon addition. VEGF165 is the 
most predominant protein, but transcripts ofVEGF 121 may 
be more abundant. VEGF206 is rarely expressed and has been 5 
detected only in fetal liver. Recently, other splice variants of 
145 and 183 aa have also been described. The 165, 189 and 
206 aa splice variants have heparin-binding domains, which 
help anchor them in extracellular matrix and are involved in 
binding to heparin sulfate and presentation to VEGF recep- 10 
tors. Such presentation is a key factor for VEGF potency (i.e., 
the heparin-binding forms are more active). Several other 
members of the VEGF family have been cloned including 
VEGF-B, -C, and -D. Placenta growth factor (PIGF) is also 
closely related to VEGF-A. VEGF-A, -B, -C, -D, and PIGF 15 
are all distantly related to platelet-derived growth factors-A 
and -B. Less is known about the function and regulation of 
VEGF -B, -C, and -D, but they do not seem to be regulated by 
the major pathways that regulate VEGF -A. 
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sequences encoding any vascular endothelial growth factor 
protein, peptide, or polypeptide having vascular endothelial 
growth factor activity. 
By "VEGF-B" is meant, protein, peptide, or polypeptide 
receptor or a derivative thereof, such as encoded by Genbank 
Accession No. NM 003377, having vascular endothelial 
growth factor type B activity. The term VEGF -B also refers to 
nucleic acid sequences encoding any VEGF -B protein, pep-
tide, or polypeptide having VEGF -B activity. 
By "VEGF -C" is meant, protein, peptide, or polypeptide 
receptor or a derivative thereof, such as encoded by Genbank 
Accession No. NM 005429, having vascular endothelial 
growth factor type C activity. The term VEGF -C also refers to 
nucleic acid sequences encoding any VEGF -C protein, pep-
tide, or polypeptide having VEGF -C activity. 
By "VEGF-D" is meant, protein, peptide, or polypeptide 
receptor or a derivative thereof, such as encoded by Genbank 
Accession No. NM 004469, having vascular endothelial 
growth factor typeD activity. The term VEGF -D also refers to 
nucleic acid sequences encoding any VEGF-D protein, pep-
tide, or polypeptide having VEGF -D activity. 
By "VEGFR" as used herein is meant, any vascular endot-
helial growth factor receptor protein, peptide, or polypeptide 
(e.g., VEGFR1, VEGFR2, orVEGFR3, including both mem-
brane bound and/or soluble forms thereof) having vascular 
endothelial growth factor receptor activity. The term VEGFR 
also refers to nucleic acid sequences encoding any vascular 
endothelial growth factor receptor protein, peptide, or 
polypeptide having vascular endothelial growth factor recep-
VEGF-A transcription is potentiated in response to 20 
hypoxia and by activated oncogenes. The transcription fac-
tors, hypoxia inducible factor-1a (hif-1a) and -2a, are 
degraded by proteosomes in normoxia and stabilized in 
hypoxia. This pathway is dependent on the Von Rippel-
Lindau gene product. Hif-1a and hif-2 a heterodimerize with 25 
the aryl hydrocarbon nuclear translocator in the nucleus and 
bind the VEGF promoter/enhancer. This is a key pathway 
expressed in most types of cells. Hypoxia inducibility, in 
particular, characterizes VEGF-A versus other members of 
the VEGF family and other angiogenic factors. 30 tor activity. 
There are three receptors in the VEGF receptor family. 
They have the common properties of multiple IgG-like extra-
cellular domains and tyrosine kinase activity. The enzyme 
domains ofVEGF receptor 1 (VEGFR1, also known as Flt-1 ), 
VEGFR2 (also known as KDR or Flk-1), and VEGFR3 (also 35 
known as Flt-4) are divided by an inserted sequence. Endot-
helial cells also express additional VEGF receptors, Neuro-
pilin-1 and Neuropilin-2. VEGF-A binds to VEGFR1 and 
VEGFR2 and to Neuropilin-1 and Neuropilin-2. PIGF and 
VEGF-B bind VEGFR1 and Neuropilin-1. VEGF-C and -D 40 
bind VEGFR3 and VEGFR2. 
By "VEGFR1," "sVEGFR1," or"sflt-1" is meant, protein, 
peptide, or polypeptide receptor or a derivative thereof, such 
as encoded by GenbankAccession No. NM 002019 or Gen-
Bank accession number U01134, having vascular endothelial 
growth factor receptor type 1 (fit) activity, for example, hav-
ing the ability to bind a vascular endothelial growth factor. 
The term VEGF 1 also refers to nucleic acid sequences encod-
ing any VEGFR1 protein, peptide, or polypeptide having 
VEGFR1 activity. The biological activity of an sF!t-1 
polypeptide may be assayed using any standard method, for 
example, by assaying sF!t-1 binding to VEGF. sF!t-1lacks the 
Accordingly, by "vascular endothelial growth factor 
(VEGF)" is meant a mmalian growth factor that is 
homologous to the growth factor defined in U.S. Pat. Nos. 
5,332,671; 5,240,848; 5,194,596; and Charnock-Janes eta!. 
(Bioi. Reproduction, 48: 1120-1128, 1993), and has VEGF 
biological activity. VEGF exists as a glycosylated homodimer 
and includes at least four different alternatively spliced iso-
forms. The biological activity of native VEGF includes the 
promotion of selective growth of vascular endothelial cells or 
umbilical vein endothelial cells and induction of angiogen-
esis. As used herein, VEGF includes any VEGF family mem-
berorisoform (e.g., VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E, VEGF189, VEGF165, orVEGF 121). Preferably, 
VEGF is the VEGF121 orVEGF165 isoform (Tischer eta!., 
J. Bioi. Chern. 266, 11947-11954, 1991; Neufed eta!. Cancer 
Metastasis 15:153-158, 1996), which is described in U.S. Pat. 
Nos. 6,447,768; 5,219,739; and 5,194,596, hereby incorpo-
rated by reference. Also included are mutant forms ofVEGF 
such as the KDR-selective VEGF and Fit-selective VEGF 
described in Gille et a!. (J. Bioi. Chern. 276:3222-3230, 
2001 ). As used herein VEGF also includes any modified 
forms of VEGF such as those described in LeCouter et a!. 
(Science 299:890-893, 2003 ). Although human VEGF is pre-
ferred, the invention is not limited to human forms and can 
include other animal forms ofVEGF (e.g. mouse, rat, dog, or 
chicken). The term VEGF also refers to nucleic acid 
transmembrane domain and the cytoplasmic tyrosine kinase 
domain of the Flt-1 receptor. sF!t-1 can bind to VEGF and 
PIGF with high affinity, but it caunot induce proliferation or 
45 angiogenesis and is therefore functionally different from the 
Flt-1 and KDR receptors. sF!t-1 was initially purified from 
human umbilical endothelial cells and later shown to be pro-
duced by trophoblast cells in vivo. As used herein, sF!t-1 
includes any sF!t-1 family member or isoform. sF!t-1 can also 
50 mean degradation products or fragments that result from 
enzymatic cleavage of the Flt-1 receptor and that maintain 
sF!t-1 biological activity. In one example, specific metallo-
proteinases released from the placenta may cleave the extra-
cellular domain of Flt-1 receptor to release theN-terminal 
55 portion ofF!t-1 into circulation. 
A soluble form of Flt-1 (sflt-1) can be detected in periph-
eral blood and is a high affinity ligand for VEGF. Soluble 
Flt-1 can be used to antagonize VEGF function. VEGFR1 and 
VEGFR2 are upregulated in tumor and proliferating endot-
60 helium, partly by hypoxia and also in response to VEGF-A 
itself. VEGFR1 and VEGFR2 can interact with multiple 
downstream signaling pathways via proteins such as PLC-g, 
Ras, She, Nck, PKC and PI3-kinase. VEGFR1 is of higher 
affinity than VEGFR2 and mediates motility and vascular 
65 permeability. VEGFR2 is necessary for proliferation. 
By "VEGFR2" is meant, protein, peptide, or polypeptide 
receptor or a derivative thereof, such as encoded by Genbank 
US 9,198,981 B2 
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Accession No. NM 002253, having vascular endothelial 
growth factor receptor type 2 (kdr) activity, for example, 
having the ability to bind a vascular endothelial growth factor. 
The term VEGF2 also refers to nucleic acid sequences encod-
ing any VEGFR2 protein, peptide, or polypeptide having 
VEGFR2 activity. 
By "VEGFR3" is meant, protein, peptide, or polypeptide 
receptor or a derivative thereof, such as encoded by Genbank 
Accession No. NM 002020 having vascular endothelial 
growth factor receptor type 3 (kdr) activity, for example, 
having the ability to bind a vascular endothelial growth factor. 
The term VEGFR3 also refers to nucleic acid sequences 
encoding any VEGFR3 protein, peptide, or polypeptide hav-
ing VEGFR3 activity. 
In one embodiment, double stranded nucleic acid molecule 
of the invention is amicroRNA (miRNA). By "micro RNA" or 
"miRNA" is meant, a small double stranded RNA that regu-
lates the expression of target messenger RNAs either by 
mRNA cleavage, translational repression/inhibition or het-
erochromatic silencing (see for example Ambros, 2004, 
Nature, 431, 350-355; Bartel, 2004, Cell, 116, 281-297; 
Cullen, 2004, Virus Research., 102, 3-9; He eta!., 2004, Nat. 
Rev. Genet., 5, 522-531; and Ying et a!., 2004, Gene, 342, 
25-28). In one embodiment, the microRNA of the invention, 
has partial complementarity (i.e., less than 100% comple-
mentarity) between the sense strand or sense region and the 
antisense strand or antisense region of the miRNA molecule 
or between the antisense strand or antisense region of the 
miRNA and a corresponding target nucleic acid molecule. 
For example, partial complementarity can include various 
mismatches or non-base paired nucleotides (e.g., 1, 2, 3, 4, 5 
or more mismatches or non-based paired nucleotides, such as 
nucleotide bulges) within the double stranded nucleic acid 
molecule, structure which can result in bulges, loops, or over-
hangs that result between the sense strand or sense region and 
the antisense strand or antisense region of the miRNA or 
between the antisense strand or antisense region of the 
miRNA and a corresponding target nucleic acid molecule. 
In another embodiment, the compounds, compositions, 
and methods provided herein have therapeutic applications. 
For example, a compound, or composition that includes the 
compound, can be administered to a subject in order to regu-
late the bioavailability or biological activity of VEGF or 
PIG F. Accordingly, a compound provided herein is believed 
to find therapeutic use for treating mammals via stimulation 
or inhibition of growth and/or differentiation and/or activa-
tion of cells susceptible to stimulation by VEGF and/or PIG F. 
Exogenous compound may be administered to a patient in 
these circumstances. A compound of the invention is clearly 
useful insofar as it can be administered to a subject having 
depressed levels (e.g., through sequestration with an inacti-
vating agent) of biologically active endogenous VEGF or 
PIG F. Such depressed levels are generally the result ofVEGF 
or PIGF interactions with an inactivating agent. An agent-
growth factor complex forms which negatively impacts the 
bioavailability or biological activity ofVEGF and/or PIGF. 
Compounds provided herein reverse the effect of the inacti-
vating agent by inhibiting, preventing or disrupting the for-
mation of such a complex. 
Accordingly, the compounds, compositions and methods 
provided herein can be used to treat conditions associated 
with decreased vascularity. For example, tissue that requires 
vascularization, neovascularization and/or revascularization 
of in a subject can be treated by a compound, composition or 
method provided herein. Such conditions include ocular dis-
orders, preeclampsia, cerebrovascular disorders, cardiovas-
cular disorders, and wound healing disorders. 
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By "ocular disease" as used herein is meant, any disease, 
condition, trait, genotype or phenotype of the eye and related 
structures as is known in the art, such as Cystoid Macular 
Edema, Asteroid Hyalosis, Pathological Myopia and Poste-
rior Staphyloma, Toxocariasis (Ocular Larva Migrans ), Reti-
nal Vein Occlusion, Posterior Vitreous Detachment, Trac-
tional Retinal Tears, Epiretinal Membrane, Diabetic 
Retinopathy, Lattice Degeneration, Retinal Vein Occlusion, 
Retinal Artery Occlusion, Macular Degeneration (e.g., age 
1 o related macular degeneration such as wet AMD or dry AMD ), 
Toxoplasmosis, Choroidal Melanoma, Acquired Retinoschi-
sis, Hollenhorst Plaque, Idiopathic Central Serous Choriore-
tinopathy, Macular Hole, Presumed Ocular Histoplasmosis 
Syndrome, Retinal Macroaneursym, Retinitis Pigmentosa, 
15 Retinal Detachment, Hypertensive Retinopathy, Retinal Pig-
ment Epithelium (RPE) Detachment, Papillophlebitis, Ocu-
lar Ischemic Syndrome, Coats' Disease, Leber's Miliary 
Aneurysm, Conjunctival Neoplasms, Allergic Conjunctivitis, 
Vernal Conjunctivitis, Acute Bacterial Conjunctivitis, Aller-
20 gic Conjunctivitis & Vernal Keratoconjunctivitis, Viral Con-
junctivitis, Bacterial Conjunctivitis, Chlamydia! & Gonococ-
cal Conjunctivitis, Conjunctival Laceration, Episcleritis, 
Scleritis, Pingueculitis, Pterygium, Superior Limbic Kerato-
conjunctivitis (SLK ofTheodore ), Toxic Conjunctivitis, Con-
25 junctivitis with Pseudomembrane, Giant Papillary Conjunc-
tivitis, Terrien's Marginal Degeneration, Acanthamoeba 
Keratitis, Fungal Keratitis, Filamentary Keratitis, Bacterial 
Keratitis, Keratitis Sicca/Dry Eye Syndrome, Bacterial 
Keratitis, Herpes Simplex Keratitis, Sterile Corneal Infil-
30 trates, Phlyctenulosis, Corneal Abrasion & Recurrent Cor-
neal Erosion, Corneal Foreign Body, Chemical Burs, Epithe-
lial Basement Membrane Dystrophy (EBMD), Thygeson's 
Superficial Punctate Keratopathy, Corneal Laceration, Salz-
mann's Nodular Degeneration, Fuchs' Endothelial Dystro-
35 phy, Crystalline Lens Subluxation, Ciliary-Block Glaucoma, 
Primary Open-Angle Glaucoma, Pigment Dispersion Syn-
drome and Pigmentary Glaucoma, Pseudoexfoliation Syn-
drome and Pseudoexfoliative Glaucoma, Anterior Uveitis, 
Primary Open Angle Glaucoma, Uveitic Glaucoma & Glau-
40 comatocyclitic Crisis, Pigment Dispersion Syndrome & Pig-
mentary Glaucoma, Acute Angle Closure Glaucoma, Ante-
rior Uveitis, Hyphema, Angle Recession Glaucoma, Lens 
Induced Glaucoma, Pseudoexfoliation Syndrome and Pseu-
doexfoliative Glaucoma, Axenfeld-Rieger Syndrome, 
45 Neovascular Glaucoma, Pars Planitis, Choroidal Rupture, 
Duane's Retraction Syndrome, Toxic/Nutritional Optic Neu-
ropathy, Aberrant Regeneration of Cranial Nerve III, Intrac-
ranial Mass Lesions, Carotid-Cavernous Sinus Fistula, Ante-
rior Ischemic Optic Neuropathy, Optic Disc Edema & 
so Papilledema, Cranial Nerve III Palsy, Cranial Nerve IV Palsy, 
Cranial Nerve VI Palsy, Cranial Nerve VII (Facial Nerve) 
Palsy, Horner's Syndrome, Internuclear Ophthalmoplegia, 
Optic Nerve Head Hypoplasia, Optic Pit, Tonic Pupil, Optic 
Nerve Head Drusen, Demyelinating Optic Neuropathy (Op-
55 tic Neuritis, Retrobulbar Optic Neuritis), Amaurosis Fugax 
and Transient Ischemic Attack, Pseudotumor Cerebri, Pitu-
itary Adenoma, Molluscum Contagiosum, Canaliculitis, Ver-
ruca and Papilloma, Pediculosis and Pthiriasis, Blepharitis, 
Hordeolum, Preseptal Cellulitis, Chalazion, Basal Cell Car-
60 cinoma, Herpes Zoster Ophthalmicus, Pediculosis & Phthiri-
asis, Blow-out Fracture, Chronic Epiphora, Dacryocystitis, 
Herpes Simplex Blepharitis, Orbital Cellulitis, Senile Entro-
pion, and Squamous Cell Carcinoma. 
By "pre-eclampsia" is meant the multi-system disorder 
65 that is characterized by hypertension with proteinuria or 
edema, or both, glomerular dysfunction, brain edema, liver 
edema, or coagulation abnormalities due to pregnancy or the 
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topulmonary septal defect, endocardial cushion defects, 
Lutembacher's Syndrome, trilogy ofFallot, ventricular heart 
septal defects. 
influence of a recent pregnancy. All forms of pre-eclampsia, 
such as premature, mild, moderate, and severe pre-eclampsia 
are included in this definition. Pre-eclampsia generally 
occurs after the 20th week of gestation. Pre-eclampsia is 
generally defined as some combination of the following 
symptoms: (1) a systolic blood pressure (BP)>140 mmHg 
and a diastolic BP>90 mmHg after 20 weeks gestation (gen-
erally measured on two occasions, 4-168 hours apart), (2) 
new onset proteinuria (by dipstik on urinanaysis, >300 mg of 
protein in a 24-hour urine collection, or a single random urine 
sample having a protein/creatinine ratio>0.3), and (3) reso-
lution of hypertension and proteinuria by 12 weeks postpar-
tum. Severe pre-eclampsia is generally defined as (1) a dias-
tolic BP> 110 mmHg (generally measured on two occasions, 
4-168 hours apart) or (2) proteinuria characterized by a mea-
surement of3.5 g or more protein in a 24-hoururine collection 
or two random urine specimens with at least 3+protein by 
dipstick. In pre-eclampsia, hypertension and proteinuria gen-
erally occur within seven days of each other. In severe pre-
eclampsia, severe hypertension, severe proteinuria and 
HELLP syndrome (hemolysis, elevated liver enzymes, low 
platelets) or eclampsia can occur simultaneously or only one 
symptom at a time. HELLP syndrome is characterized by 
evidence of thrombocytopenia ( <1 00000 cells/ul), increased 
LDH (>600 IU/L) and increasedAST (>70 IU/L). Occasion-
ally, severe pre-eclampsia can lead to the development of 
seizures. This severe form of the syndrome is referred to as 
"eclampsia." Eclampsia can also include dysfunction or dam-
age to several organs or tissues such as the liver (e.g., hepa-
tocellular damage, periportal necrosis) and the central ner-
vous system (e.g., cerebral edema and cerebral hemorrhage). 
The etiology of the seizures is thought to be secondary to the 
development of cerebral edema and focal spasm of small 
blood vessels in the kidney. 
Cardiovascular disorders also include, but are not limited 
to, heart disease, such as arrhythmias, carcinoid heart disease, 
high cardiac output, low cardiac output, cardiac tamponade, 
endocarditis (including bacterial), heart aneurysm, cardiac 
arrest, congestive heart failure, congestive cardiomyopathy, 
paroxysmal dyspnea, cardiac edema, heart hypertrophy, con-
10 gestive cardiomyopathy, left ventricular hypertrophy, right 
ventricular hypertrophy, post-infarction heart rupture, ven-
tricular septal rupture, heart valve diseases, myocardial dis-
eases, myocardial ischemia, pericardia! effusion, pericarditis 
15 (including constrictive and tuberculous), pneumopericar-
dium, postpericardiotomy syndrome, pulmonary heart dis-
ease, rheumatic heart disease, ventricular dysfunction, hype-
remia, cardiovascular pregnancy complications, Scimitar 
Syndrome, cardiovascular syphilis, and cardiovascular tuber-
20 culosis. 
Arrhythmias include, but are not limited to, sinus arrhyth-
mia, atrial fibrillation, atrial fluner, bradycardia, extrastole, 
Adams-Stokes Syndrome, bundle-branch block, sinoatrial 
block, long QT syndrome, parasystole, Lown-Ganong-Le-
25 vine Syndrome, Mahaim-type pre-excitation syndrome, 
Wolff-Parkinson-White syndrome, sick sinus syndrome, 
tachycardias, and ventricular fibrillation. Tachycardias 
include paroxysmal tachycardia, supraventricular tachycar-
dia, accelerated idioventricular rhythm, atrioventricular 
30 nodal reentry tachycardia, ectopic atrial tachycardia, ectopic 
junctional tachycardia, sinoatrial nodal reentry tachycardia, 
sinus tachycardia, Torsades de Pointes, and ventricular tachy-
cardia. 
Myocardial diseases include, but are not limited to, alco-
Several factors have been-reported to have an association 
with fetal and placental development and, more specifically, 
with pre-eclampsia. They include vascular endothelial 
growth factor (VEGF), soluble Flt-1 receptor (sF!t-1), and 
placental growth factor (PIG F). As previously noted, VEGF is 
35 holic cardiomyopathy, congestive cardiomyopathy, hyper-
trophic cardiomyopathy, aortic subvalvular stenosis, pulmo-
nary subvalvular stenosis, restrictive cardiomyopathy, 
Chagas cardiomyopathy, endocardial fibroelastosis, 
endomyocardial fibrosis, Kearns Syndrome, myocardial rep-
40 erfusion injury, and myocarditis. an endothelial cell-specific mitogen, an angiogenic inducer, 
and a mediator of vascular permeability. VEGF has also been 
shown to be important for glomerular capillary repair. VEGF 
binds as a homodimer to one of two homologous membrane-
spanning tyrosine kinase receptors, the fms-like tyrosine 
kinase (Flt-1) and the kinase domain receptor (KDR), which 45 
are differentially expressed in endothelial cells obtained from 
many different tissues. Flt-1, but not KDR, is highly 
expressed by trophoblast cells which contribute to placental 
formation. PIGF is a VEGF family member that is also 
involved in placental development. PIGF is expressed by 50 
cytotrophoblasts and syncytiotrophoblasts and is capable of 
inducing proliferation, migration, and activation of endothe-
lial cells. PIGF binds as a homodimer to the Fit -1 receptor, but 
not the KDR receptor. Both PIGF and VEGF contribute to the 
mitogenic activity and angiogenesis that are critical for the 55 
developing placenta. 
By "cardiovascular disorders" is meant cardiovascular 
abnormalities, such as arteria-arterial fistula, arteriovenous 
fistula, cerebral arteriovenous malformations, congenital 
heart defects, pulmonary atresia, and Scimitar Syndrome. 60 
Congenital heart defects include, but are not limited to, aortic 
coarctation, cortriatriatum, coronary vessel anomalies, criss-
cross heart, dextrocardia, patent, ductus arteriosus, Ebstein's 
anomaly, Eisenmenger complex, hypoplastic left heart syn-
drome, levocardia, tetralogy of fallot, transposition of great 65 
vessels, double outlet right ventricle, tricuspid atresia, persis-
tent truncus arteriosus, and heart septal defects, such as aor-
Myocardial ischemias include, but are not limited to, coro-
nary disease, such as angina pectoris, coronary aneurysm, 
coronary arteriosclerosis, coronary thrombosis, coronary 
vasospasm, myocardial infarction and myocardial stunning. 
Cardiovascular diseases also include vascular diseases 
such as aneurysms, angiodysplasia, angiomatosis, bacillary 
angiomatosis, Rippel-Lindau Disease, Klippel-Trenaunay-
Weber Syndrome, Sturge-Weber Syndrome, angioneurotic 
edema, aortic diseases, Takayasu's Arteritis, aortitis, Ler-
iche's Syndrome, arterial occlusive diseases, arteritis, enar-
teritis, polyarteritis nodosa, cerebrovascular disorders, dia-
betic angiopathies, diabetic retinopathy, embolisms, 
thrombosis, erythromelalgia, hemorrhoids, hepatic vena-oc-
clusive disease, hypertension, hypotension, ischemia, periph-
eral vascular diseases, phlebitis, pulmonary vena-occlusive 
disease, Raynaud's disease, CREST syndrome, retinal vein 
occlusion, Scimitar syndrome, superior vena cava syndrome, 
telangiectasia, atacia telangiectasia, hereditary hemorrhagic 
telangiectasia, varicocele, varicose veins, varicose ulcer, vas-
culitis, and venous insufficiency. 
Aneurysms include, but are not limited to, dissecting aneu-
rysms, false aneurysms, infected aneurysms, ruptured aneu-
rysms, aortic aneurysms, cerebral aneurysms, coronary aneu-
rysms, heart aneurysms, and iliac aneurysms. 
Arterial occlusive diseases include, but are not limited to, 
arteriosclerosis, intermittent claudication, carotid stenosis, 
fibromuscular dysplasias, mesenteric vascular occlusion, 
US 9,198,981 B2 
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Moyamoya disease, renal artery obstruction, retinal artery 
occlusion, and thromboangiitis obliterans. 
Cerebrovascular disorders include, but are not limited to, 
carotid artery diseases, cerebral amyloid angiopathy, cerebral 
aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral 
arteriovenous malformation, cerebral artery diseases, cere-
bral embolism and thrombosis, carotid artery thrombosis, 
sinus thrombosis, Wallenberg's syndrome, cerebral hemor-
rhage, epidural hematoma, subdural hematoma, subaraxh-
noid hemorrhage, cerebral infarction, cerebral ischemia (in- 10 
eluding transient), subclavian steal syndrome, periventricular 
leukomalacia, vascular headache, cluster headache, 
migraine, and vertebrobasilar insufficiency. 
22 
ing. In a similar fashion, the compound can be used in plastic 
surgery when reconstruction is required following a bum or 
other trauma, or for cosmetic purposes. 
Angiogenesis is also important in keeping wounds clean 
and non-infected. The compound can therefore be used in 
association with general surgery and following the repair of 
cuts and lacerations. It is particularly useful in the treatment 
of abdominal wounds with a high risk of infection. Neovas-
cularization is also key to fracture repair, since blood vessels 
develop at the site of bone injury. Administration of the com-
pound to the site of a fracture is therefore another utility. 
In cases where the compound is being used for topical 
wound healing, as described above, it may be administered by 
any of the routes described below for the re-endothelializa-
tion of vascular tissue, or more preferably by topical means. 
In these cases, it will be administered as either a solution, 
spray, gel, cream, ointment, or dry powder directly to the site 
of injury. Slow-release devices directing the compound to the 
injured site will also be used. In topical applications, the 
Embolisms include, but are not limited to, air embolisms, 
anmiotic fluid embolisms, cholesterol embolisms, blue toe 15 
syndrome, fat embolisms, pulmonary embolisms, and thro-
moboembolisms. Tbrombosis include, but are not limited to, 
coronary thrombosis, hepatic vein thrombosis, retinal vein 
occlusion, carotid artery thrombosis, sinus thrombosis, Wal-
lenberg's syndrome, and thrombophlebitis. 
Ischemic disorders include, but are not limited to, cerebral 
ischemia, ischemic colitis, compartment syndromes, anterior 
compartment syndrome, myocardial ischemia, reperfusion 
injuries, and peripheral limb ischemia. Vasculitis includes, 
but is not limited to, aortitis, arteritis, Behcet's Syndrome, 25 
Churg-Strauss Syndrome, mucocutaneous lymph node syn-
drome, thromboangiitis obliterans, hypersensitivity vasculi-
20 compound will be applied at a concentration ranging from 
about 50 to 1,000 ug/mL, either in a single application, or in 
dosing regimens that are daily or every few days for a period 
of one week to several weeks. Generally, the amount of topi-
cal formulation administered is that which is sufficient to 
tis, Schoenlein-Henoch purpura, allergic cutaneous vasculi-
tis, and Wegener's granulomatosis. 
apply from about 0.1 to 100 ug/cm2 of the compound, based 
on the surface area of the wound. 
The compound can be used as a post-operative wound 
healing agent in balloon angioplasty, a procedure in which 
vascular endothelial cells are removed or damaged, together 
with compression of atherosclerotic plaques. The compound 
can be applied to inner vascular surfaces by systemic or local 
intravenous application either as intravenous bolus injection 
or infusions. If desired, the compound can be administered 
over time using a micrometering pump. Suitable composi-
tions for intravenous administration comprise the compound 
in an amount effective to promote endothelial cell growth and 
a parenteral carrier material. The compound can be present in 
the composition over a wide range of concentrations, for 
example, from about 50 ug/mL to about 1,000 ug/mL using 
injections of 3 to 10 mL per patient, administered once or in 
dosing regimens that allow for multiple applications. Any of 
the known parenteral carrier vehicles can be used, such as 
normal saline or 5-10% dextrose. 
The compound can also be used to promote endothelial-
ization in vascular graft surgery. In the case of vascular grafts 
using either transplanted vessels or synthetic material, for 
example, the compound can be applied to the surfaces of the 
graft and/or at the junctions of the graft and the existing 
vasculature to promote the growth of vascular endothelial 
By "wound healing" is meant any disorder, disease or 30 
injury associated with a tissue that would benefit from 
increased vascularization. Accordingly, "wound healing" 
encompasses facilitating angiogenesis in the context vascu-
larization of, for example, grafts, organ transplantation, or 
any other activity associated with tissue regeneration. Various 35 
potential therapeutic uses of a compound include those in 
which increasing the bioavailability of VEGF or PlGF is 
useful. Examples of these include uses associated with the 
vascular endothelium, such as the treatment of traumata to the 
vascular network, in view of the demonstrated rapid promo- 40 
tion by VEGF of the proliferation of vascular endothelial cells 
that would surround the traumata. Examples of such traumata 
that could be so treated include, but are not limited to, surgical 
incisions, particularly those involving the heart, wounds, 
including lacerations, incisions, and penetrations of blood 45 
vessels, and surface ulcers involving the vascular endothe-
lium such as diabetic, hemophiliac, and varicose ulcers. Other 
physiological conditions that could be improved based on the 
selective mitogenic character of the compound are also 
included herein. so cells. For such applications, the compound can be applied 
intravenously as described above for balloon angioplasty or it 
can be applied directly to the surfaces of the graft and/or the 
existing vasculature either before or during surgery. 
For the traumatic indications referred to above, the com-
pound will be formulated and dosed in a fashion consistent 
with good medical practice taking into account the specific 
disorder to be treated, the condition of the individual patient, 
the site of delivery of the compound, the method of adminis-
tration, and other factors known to practitioners. Accordingly, 
the compound can be included in a composition, such as a 
pharmaceutically-acceptable composition, for administra-
tion to the site of trauma. 
By "Pharmaceutically acceptable composition" or "thera-
55 peutic formulation" is meant a carrier that is physiologically 
acceptable to the treated mammal while retaining the thera-
peutic properties of the compound with which it is adminis-
tered. One exemplary pharmaceutically acceptable carrier 
Additional indications for compounds provided herein 60 
include the treatment of full-thickness wounds such as dermal 
substance is physiological saline. Other physiologically 
acceptable carriers and their formulations are known to one 
skilled in the art and described, for example, in Remington's 
ulcers, including the categories of pressure sores, venous 
ulcers, and diabetic ulcers, as well as of full-thickness bums 
and injuries where angiogenesis is required to prepare the 
bum or injured site for a skin graft or flap. In this case the 
compound is either applied directly to the site or it is used to 
soak the skin or flap that is being transplanted prior to graft-
Pharmaceutical Sciences, (20th edition), ed. A. Gennaro, 
2000, Lippincott, Williams & Wilkins, Philadelphia, Pa. 
Such compositions are prepared for storage by mixing 
65 compound having the desired degree of purity with optional 
physiologically acceptable carriers, excipients, or stabilizers 
(Remington's Pharmaceutical Sciences, 16th edition, Osol, 
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A., Ed., [1980]), in the form oflyophilized cake or aqueous 
solutions. Acceptable carriers, excipients, or stabilizers are 
nontoxic to recipients at the dosages and concentrations 
employed, and include buffers such as phosphate, citrate, and 
other organic acids; antioxidants including ascorbic acid; low 
molecular weight (less than about 10 residues) polypeptides; 
proteins, such as serum albumin, gelatin, or immunoglobu-
lins; hydrophilic polymers such as polyvinylpyrrolidone; 
amino acids such as glycine, glutamine, asparagine, arginine, 
24 
Sustained-release compound compositions also include 
liposomally entrapped compound. Liposomes containing 
compound are prepared by methods known per se: DE 3,218, 
121; Epsteinet a!., Proc. Natl.Acad. Sci. USA, 82:3688-3692 
(1985); Hwang eta!., Proc. Nat!. Acad. Sci. USA, 77:4030-
4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; 
EP 142,641; Japanese patent application 83-118008; U.S. 
Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordi-
narily the liposomes are of the small (about 200-800 Ang-
stroms) nnilamellar type in which the lipid content is greater 
than about 30 mol % cholesterol, the selected proportion 
being adjusted for the optimal compound therapy. 
or lysine; monosaccharides, disaccharides, and other carbo- 10 
hydrates including glucose, marmose, or dextrins; chelating 
agents such as EDTA; sugar alcohols such as mannitol or 
sorbitol; salt-forming counter-ions such as sodium; and/or 
non-ionic surfactants such as Tween, Pluronics or polyethyl-
ene glycol (PEG). 
The compound also may be entrapped in microcapsules 
prepared, for example, by coacervation techniques or by 
interfacial polymerization (for example, hydroxymethylcel-
lulose or gelatin-microcapsules and poly-[ methylmethacy-
late] microcapsules, respectively), in colloidal drug delivery 20 
systems (for example, liposomes, albumin microspheres, 
microemulsions, nano-particles, and nanocapsules), or in 
macroemulsions. 
When applied topically, the compound is suitably com-
15 bined with other ingredients, such as carriers and/or adju-
vants. There are no limitations on the nature of such other 
In general, a compound to be used for in vivo administra-
tion must be sterile. This is readily accomplished by filtration 25 
through sterile filtration membranes, prior to or following 
lyophilization and reconstitution. compound ordinarily will 
be stored in lyophilized form or in solution. 
Therapeutic compound compositions generally are placed 
into a container having a sterile access port, for example, an 30 
intravenous solution bag or vial having a stopper pierceable 
by a hypodermic injection needle. 
The route of compound administration is in accord with 
known methods, e.g., those routes set forth above for specific 
indications, as well as the general routes of injection or infu- 35 
sian by intravenous, intraperitoneal, intracerebral, intramus-
cular, intraocular, intraarterial, or intralesional means, or sus-
tained release systems as noted below. A compound provided 
herein can be administered continuously by infusion or by 
bolus injection. Generally, where the disorder permits, one 40 
should formulate and dose the compound for site-specific 
delivery. This is convenient in the case of wounds and ulcers. 
Suitable examples of sustained-release preparations include 
semi-permeable matrices of solid hydrophobic polymers con-
taining the protein, which matrices are in the form of shaped 45 
articles, e.g., films, or microcapsules. Examples of sustained-
release matrices include polyesters, hydro gels [e.g., poly(2-
hydroxyethyl-methacrylate) as described by Langer eta!., J. 
Biomed. Mater. Res., 15:167, 1981 and Langer, Chern. Tech., 
12:98, 1982 or poly(vinylalcohol)], polylactides (U.S. Pat. 50 
No. 3,773,919, EP 58,481), copolymers of L-glutamic acid 
and gamma ethyl-L-glutamate (Sidman eta!., Biopolymers, 
22:547, 1983), non-degradable ethylene-vinyl acetate 
(Langer et a!., supra), degradable lactic acid-glycolic acid 
copolymers such as the Lupron Depot™ (injectable micro- 55 
spheres composed oflactic acid-glycolic acid copolymer and 
leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid 
(EP 133,988). 
While polymers such as ethylene-vinyl acetate and lactic 
acid-glycolic acid enable release of molecules for over 100 60 
days, certain hydrogels release proteins for shorter time peri-
ods. When encapsulated compounds remain in the body for 
an extended period of time, they may denature or aggregate as 
a result of exposure to moisture at 37° C., resulting in a loss of 
biological activity. Rational strategies can be devised for 65 
nucleic acid and/or protein stabilization depending on the 
mechanism involved. 
ingredients, except that they must be pharmaceutically 
acceptable and efficacious for their intended administration, 
and carmot degrade the activity of the active ingredients of the 
composition. Examples of suitable vehicles include oint-
ments, creams, gels, or suspensions, with or without purified 
collagen. The compositions also may be impregnated into 
transdermal patches, plasters, and bandages, preferably in 
liquid or semi-liquid form. 
For obtaining a gel formulation, the compound formulated 
in a liquid composition may be mixed with an effective 
amount of a water-soluble polysaccharide or synthetic poly-
mer such as PEG to form a gel of the proper viscosity to be 
applied topically. The polysaccharide that may be used 
includes, for example, cellulose derivatives such as etherified 
cellulose derivatives, including alkyl celluloses, hydroxy-
alkyl celluloses, and alkylhydroxyalky celluloses, for 
example, methylcellulose, hydroxyethyl cellulose, car-
boxymethyl cellulose, hydroxypropyl methylcellulose, and 
hydroxypropyl cellulose; starch and fractionated starch; agar; 
alginic acid and alginates; gum arabic; pullullan; agarose; 
carrageenan; dextrans; dextrins; fructans; inulin; mannans; 
xylans; arabinans; chitosans; glycogens; glucans; and syn-
thetic biopolymers; as well as gums such as xanthan gum; 
guar gum; locust bean gum; gum arabic; tragacanth gum; and 
karaya gum; and derivatives and mixtures thereof. The pre-
ferred gelling agent herein is one that is inert to biological 
systems, nontoxic, simple to prepare, and not too runny or 
viscous, and will not destabilize the compound held within it. 
Preferably the polysaccharide is an etherified cellulose 
derivative, more preferably one that is well defined, purified, 
and listed in USP, e.g., methylcellulose and the hydroxyalkyl 
cellulose derivatives, such as hydroxypropyl cellulose, 
hydroxyethyl cellulose, and hydroxypropyl methylcellulose. 
Most preferred herein is methylcellulose. 
The polyethylene glycol useful for gelling is typically a 
mixture of! ow and high molecular weight PEGs to obtain the 
proper viscosity. For example, a mixture of a PEG of molecu-
lar weight 400-600 with one of molecular weight 1500 would 
be effective for this purpose when mixed in the proper ratio to 
obtain a paste. 
The term "water soluble" as applied to the polysaccharides 
and PEGs is meant to include colloidal solutions and disper-
sions. In general, the solubility of the cellulose derivatives is 
determined by the degree of substitution of ether groups, and 
the stabilizing derivatives useful herein should have a suffi-
cient quantity of such ether groups per anhydroglucose nnit in 
the cellulose chain to render the derivatives water soluble. A 
degree of ether substitution of at least 0.35 ether groups per 
anhydroglucose unit is generally sufficient. Additionally, the 
cellulose derivatives may be in the form of alkali metal salts, 
for example, the Li, Na, K, orCs salts. 
US 9,198,981 B2 
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If methylcellulose is employed in the gel, preferably it 
comprises about 2-5%, more preferably about 3%, of the gel 
and the compound is present in an amount of about 300-1000 
mg per ml of gel. 
An effective amount of compound to be employed thera-
peutically will depend, for example, upon the therapeutic 
objectives, the route of administration, and the condition of 
the patient. Accordingly, it will be necessary for the therapist 
26 
tion in a tissue, such as ocular or placental tissue. Preferably, 
the test compound prevents, inhibits or disrupts the ability of 
an FLT gene product to interact with VEGF or PlGF and 
inhibit or antagonize VEGF or PlGF activity. In this aspect of 
the invention, ocular tissue associated with, or derived from, 
a test animal, such as a mouse, rat, rabbit, monkey, pig, etc. 
can be used in the screening method. The candidate drug or 
test compound is administered to the ocular tissue at various 
times and at various locations (as described throughout the to titer the dosage and modifY the route of administration as 
required to obtain the optimal therapeutic effect. Typically, 
the clinician will administer the compound until a dosage is 
reached that achieves the desired effect. A typical daily dos-
age for systemic treatment might range from about 1 ug/kg to 
10 specification). Subsequently, the tissue is monitored for the 
appearance of neovascularization, or for an increase on the 
bioavailability or biological activity of a growth factor such as 
VEGF. 
up to 1 0 mg/kg or more, depending on the factors mentioned 
above. As an alternative general proposition, the compound is 15 
formulated and delivered to the target site or tissue at a dosage 
capable of establishing in the tissue a compound level greater 
than about 0.1 ng/cc up to a maximum dose that is efficacious 
but not unduly toxic. This intra-tissue concentration should 
be maintained if possible by continuous infusion, sustained 20 
release, topical application, or injection at empirically deter-
mined frequencies. The progress of this therapy is easily 
monitored by conventional assays. 
It is within the scope hereof to combine "compound 
therapy" with other novel or conventional therapies (e.g., 25 
growth factors such as VEGF, PlGF, acidic or basic fibroblast 
growth factor (aFGF or bFGF, respectively), platelet-derived 
growth factor (PDGF), insulin-like growth factor (IGF-I or 
IGF-II), nerve growth factor (NGF), anabolic steroids, EGF 
or TGF -alpha) for enhancing the activity of any of the growth 30 
factors, including the compound, in promoting cell prolifera-
tion and repair. 
It is not necessary that such co-treatment drugs be included 
per se in the compositions of this invention, although this will 
Exemplary test compounds include siNA molecules that 
are active in mediating RNA interference against a VEGF 
and/or PlGF inactivating agent. Additional exemplary test 
compounds include organic molecules, peptides, peptide 
mimetics, polypeptides, nucleic acids, and antibodies that 
bind to a soluble inactivating agent. Optionally, compounds 
identified in any of the assays described herein may be con-
firmed as useful in an assay for compounds that increase the 
bioavailability or biological activity ofVEGF or PlGF. 
In general, compounds capable of decreasing the inactivat-
ing activity of an agent can be identified from large libraries 
of both natural product or synthetic (or semi-synthetic) 
extracts or chemical libraries or from polypeptide or nucleic 
acid libraries, according to methods known in the art. Those 
skilled in the field of drug discovery and development will 
understand that the precise source of test extracts or com-
pounds is not critical to the screening procedure(s) of the 
invention. Compounds used in screens may include known 
compounds (for example, known therapeutics used for other 
diseases or disorders). Alternatively, virtually any number of 
unknown chemical extracts or compounds can be screened 
using the methods described herein. Examples of such 
extracts or compounds include, but are not limited to, plant-, 
fungal-, prokaryotic- or animal-based extracts, fermentation 
broths, and synthetic compounds, as well as modification of 
existing compounds. Numerous methods are also available 
be convenient where such drugs are proteinaceous. Such 35 
admixtures are suitably administered in the same manner and 
for the same purposes as the compound used alone. The useful 
molar ratio of compound to such secondary growth factors is 
typically 1:0.1-10, with about equimolar amounts being pre-
ferred. 40 for generating random or directed synthesis (e.g., semi-syn-
thesis or total synthesis) of any number of chemical com-
pounds, including, but not limited to, saccharide-, lipid-, pep-
tide-, and nucleic acid-based compounds. Synthetic 
As discussed throughout the present specification, the 
inventors have identified a unique interaction between growth 
factors and inactivating agents in ocular tissue. The interac-
tion effectively results in the inactivation of the growth factors 
by sequestration in complexes. In view of this discovery, the 45 
present specification not only provides novel compounds for 
regulating the bioavailability of growth factors, but also pro-
vides mechanisms for identifying additional compounds 
which modulate such interactions. Accordingly, based on 
these discoveries, any number of methods are available for 50 
carrying out screening assays to identify new candidate com-
pounds that alter the ability of an inactivating agent to seques-
ter a growth factor. 
Thus, in another embodiment, provided herein are methods 
of identifying a compound that regulates the bioavailability or 55 
biological activity of VEGF or PlGF in vivo or in situ. In 
general, the method includes contacting corneal tissue with a 
test compound that regulates, or is believed to regulate, the 
expression of a VEGF or PlGF inactivating agent, or the 
ability of the VEGF or PlGF inactivating agent to bind to 60 
VEGF or PlGF. The bioavailability or biological activity of 
VEGF or PlGF can be measured and the compound identified 
compound libraries are commercially available from Bran-
don Associates (Merrimack, N.H.) and Aldrich Chemical 
(Milwaukee, Wis.). Alternatively, libraries of natural com-
pounds in the form of bacterial, fungal, plant, and animal 
extracts are commercially available from a number of 
sources, including Biotics (Sussex, UK), Xenova (Slough, 
UK), Harbor Branch Oceangraphics Institute (Ft. Pierce, 
Fla.), and PharmaMar, U.S.A. (Cambridge, Mass.). In addi-
tion, natural and synthetically produced libraries are pro-
duced, if desired, according to methods known in the art, e. g., 
by standard extraction and fractionation methods. Further-
more, if desired, any library or compound is readily modified 
using standard chemical, physical, or biochemical methods. 
EXAMPLES 
The invention is illustrated in the following examples, 
which are provided by way of illustration and are not intended 
to be limiting. 
by its effect on the bioavailability or biological activity of 
VEGF or PlGF. 
There is provided a method for screening candidate com-
pounds that modulate the ability of an inactivating agent to 
interact with VEGF or PlGF thereby promoting vasculariza-
Corneal avascularity is required for optical clarity and opti-
mal vision and has enabled the cornea to become the lead 
65 platform for validating pro- and anti -angiogenic strategies for 
myriad disorders. Yet the molecular underpinnings of the 
avascular phenotype have until now remained obscure and are 
US 9,198,981 B2 
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all the more remarkable given the presence of vascular endot-
helial growth factor (VEGF)-A, a potent stimulator of angio-
genesis, in the cornea and its proximity to vascularized tis-
sues. The present studies show that the cornea expresses 
soluble VEGF receptor-! (sVEGFR-1; 1 also known as sflt-1) 5 
and that suppression of this endogenous VEGF-A trap by 
neutralizing antibodies, RNA interference, or Cre-lox medi-
ated gene disruption abolishes corneal avascularity in mice. 
The spontaneously vascularized corneas of corn! and 
Pax6+1- mice and Pax6+1- patients with aniridia are deficient 10 
in sflt-1. Recombinant sflt-1 administration rescues corneal 
avascularity in corn! and Pax6+1- mice. Manatees, the only 
known creatures to uniformly have vascularized corneas, do 
not express sflt-1, whereas the avascular corneas of dugongs, 
also members of the order Sirenia, elephants, the closest 15 
extant terrestrial phylogenetic relatives of manatees, and 
other marine mammals (dolphins, whales) contain sflt-1, 
indicating a crucial, evolutionarily conserved role. The rec-
ognition that sflt-1 is essential to shielding vascular apartheid 
in the cornea provides a platform for modulating angiogen- 20 
esis and treating neovascular diseases. 
Despite its widespread use as a readout template, the 
molecular foundations of corneal avascularity remain nebu-
lous. In the last decade numerous anti-angiogenic molecules 
such as angiostatin, endostatin, interleukin-1 receptor antago- 25 
nist, pigment epithelium derived factor, and thrombospon-
dins were identified in the cornea (reviewed in Chang et a!., 
Curr. Opin. Ophthalmol. 12:242, 2001), leading to recogni-
tion of their tumor suppressive, atherosclerotic plaque growth 
inhibitory, or wound healing modulatory roles. None of these 30 
molecules, however, are singly requisite for corneal avascu-
larity because mice deficient in any of them retain normal 
corneal phenotypes, engendering the view of multiply redun-
dant mechanisms of corneal avascularity. The search for 
angiogenesis inhibitors to treat atherosclerosis, cancer, dia- 35 
betic kidney and retina damage, macular degeneration, and 
rheumatoid arthritis often relies on initial efficacy testing in 
the cornea for it is exquisitely devoid ofblood vessels despite 
being surrounded by the highly vascular conjunctiva (FIG. 1, 
panel A). The cornea is ideal for understanding the ability of 40 
tissues to demarcate vascular ingrowth and identifYing effi-
cacy of therapies against known angiogenic stimuli. 
The present studies have determined, for the first time, that 
the cornea contained VEGF -A, but nearly all of it was bound 
(FIG. 1, panel B). To reconcile the paradoxical presence of 45 
this potent pro-angiogenic molecule in an avascular tissue, a 
counterbalancing expression of sflt-1 was identified. sflt-1 is 
an alternatively spliced secreted isoform of membrane bound 
flt-1 (mbflt-1 ), a cell surface receptor. sflt-1 lacks the trans-
membrane (tm) and tyrosine kinase (tk) domains and can act 50 
as a manacle for VEGF-A (Kendall & Thomas, Proc. Nat!. 
Acad. Sci. USA, 90:10705, 1993). sflt-1 mRNAandprotein 
were identified in the cornea (FIG. 1, panels C-G); in contrast, 
mbflt-1 was present in the conjunctiva but not detectable in 
the cornea (FIG. 1, panel G). sflt-1 was present extracellu- 55 
larly. In vivo interaction between sflt-1 and VEGF-A was 
confirmed by immunoprecipitation (FIG. 1, panel H) and 
corroborated by immunostaining. 
sflt-1 preservation of corneal avascularity was confirmed in 
mice. First, corneal injections of neutralizing antibody 60 
against flt-1 were performed with fellow eyes receiving iso-
type control antibody. Eyes treated with blocking antibody 
consistently developed corneal vascularization (CV) from the 
limbus within 1 day, whereas those treated with control anti-
body did not (P<O.OOl). Free VEGF-A was greater in anti- 65 
flt-1 antibody-treated corneas than in control treated corneas, 
indicating that sequestration ofVEGF-A by sflt-1 maintains 
28 
corneal avascularity. This was confirmed by demonstrating 
that concomitantly treating corneas with neutralizing anti-
VEGF-A antibody, but not with isotype-control antibody, 
prevented CV induced by the anti-flt-1 antibody (P=0.029). 
Because the anti-flt-1 antibody would theoretically block 
ligand-binding ofbothmbflt-1 and sflt-1 (although the former 
is undetectable in the cornea), this antibody was tested in flt-1 
tyrosine kinase_;_ (flt-1 tk_1_) mice, which are deficient in 
receptor ligation induced signaling. The anti-fit -1 antibody, 
but not control, induced CV in flt-1 tk_;_ eyes as well 
(P=0.029), indicating that the vascular phenotype resulted 
from suppression of sflt-1 function and not interference with 
flt-1 signaling. Subconjunctival injection of anti-flt-1 anti-
body, which eliminates the confounding effect of corneal 
trauma, also elicited CV (P=O.OOS). 
In another embodiment, sflt-1 expression was condition-
ally regulated by genomic deletion. sflt-1 expression was 
suppressed by conditional Cre-lox mediated gene ablation 
because flt-1 deletion is lethal. Corneal injection of plasmid 
encoding Cre recombinase (pCre ), but not of pNull, induced 
CV in flt-1 1oxP!loxP mouse eyes (P<O.OOl) within 2 days. Cre 
expression was accompanied by significantly reduced sflt-1 
and increased free VEGF-A. Neither plasmid induced CV in 
wild-type mice. To avoid injection trauma, a cell permeable 
enzymatically active Cre containing a nuclear localization 
sequence (NLS-Cre) was delivered to the cornea by topical 
eye drops (FIG. 2, panels A-D). NLS-Cre, but not NLS-~­
galactosidase, induced CV in flt-1 1oxP!loxP mouse eyes 
(P<O.OOl) within 2 days (FIG. 2, panels E and F). Neither 
NLS-enzyme induced CV in wild-type mice (FIG. 2, panels 
GandH). 
In another embodiment, sflt-1 expression was regulated 
using RNA interference (RNAi) via corneal injection of plas-
mid expressing a short hairpin RNA (shRNA) targeted 
against a sequence in the unique carboxyl-terminus region of 
sflt-1 (pshRNA-sflt-1 ). The control was plasmid expressing a 
shRNA targeted against a sequence in the unique carboxyl-
terminus region of mbflt-1 not present in sflt-1 (pshRNA-
mbflt-1). pshRNA-sflt-1, but not pshRNA-mbflt-1, substan-
tially reduced both sflt-1 mRNA and protein, indicating that 
knockdown was through RNAi (FIG. 3, panels A and B), and 
increased free VEGF-A (FIG. 3, panel C), corroborating the 
thesis that sflt-1 sequesters VEGF -A to maintain physiologi-
cal avascularity. pshRNA-sflt-1, but not pshRNA-mbflt-1, 
consistently induced CV within 3 days after injection 
(P<O.OOOl) (FIG. 3, panels D-F). pshRNA-sflt-1 also induced 
CV in mice systemically depleted of macrophages and neu-
trophils by clodronate liposomes and anti-Gr-1 antibody, 
indicating that CV was not induced by infiltration of inflam-
matory cells and their delivery of VEGF-A. Further, 
pshRNA-sflt-1 did not elevate VEGF-A mRNA. 
In addition to sflt-1, the transmembrane domain of flt-1 
(flt-1-TM) also can trap VEGF-A. flt-1 tk_;_ mice (n>60), 
which retain expression of sflt-1 and flt-1-TM, have avascular 
corneas just as wild-type mice. pshRNA-sflt-1, but not 
pshRNA-mbflt-1, induced CV in flt-1 tk_;_ eyes (P=0.029) 
just as in wild-type eyes, indicating that sflt-1 and not flt-1-
TM is required for corneal avascularity. 
Apart from VEGF-A, sflt-1 also binds VEGF-B and pla-
centa growth factor (PlGF). Expression of these alternate 
ligands in mouse corneas was much less than that ofVEGF-
A. Moreover, pshRNA-sflt-1, but not pshRNA-mbflt-1, 
induced CV both in Vegfb_;_ (P=0.029) and Plgr-1-
(P<O.OOOl) mice, supporting the contention that CV results 
from desequestration ofVEG F-A from sflt -1. Direct evidence 
for this assertion was obtained by demonstrating that CV 
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induced by pshRNA-sflt-1 in wild-type mice was prevented 
by a neutralizing anti-VEGF-A antibody but not by isotype-
control antibody (P=0.008). 
pshRNAs can inhibit gene expression nonspecifically via 
interferon (IFN)-mediated responses; however, pshRNA -sflt-
1 induced CV in Ifnarl_;_ and Ifng_;_ mice just as in wild-
type mice, indicating that CV was not attributable to IFN 
response effectors. To examine whether other off-target 
effects might be responsible for CV induced by pshRNA-sflt-
1, a p2 shRNA-sflt-1 targeted against a different sequence in 
the unique carboxyl terminus region of sflt-1 was synthe-
sized. Corneal injection of p2 shRNA-sflt-1 also induced CV 
in wild-type mice, making it unlikely that off-target effects, 
which are sequence-specific and not target-specific, were 
responsible for loss of corneal avascularity. 
To confirm that CV induced by pshRNA-sflt-1 was mecha-
nistically linked to sflt-1 knockdown, a plasmid coding for a 
"hardened-target" version of sflt-1 (psflt-1 *) containing 
seven translationally silent wobble position mutations render-
ing expressed sflt-1 refractory to pshRNA-sflt-1 was devel-
oped. psflt-1 *,but not psflt-1, prevented suppression of sflt-1 
and CV development in eyes treated with pshRNA-sflt-1 
(P=0.008); this functional control definitively established that 
the angiogenic phenotype was due to RNAi -mediated knock-
down of sflt-1. Genetic, transcriptional, and protein-targeting 
suppression of sflt -1 all induced CV, demonstrating that sflt -1 
is the preeminent molecular defender of corneal avascularity. 
30 
African (Loxodanta africana) elephants, the closest extant 
terrestrial phylogenetic relatives of manatees, did (FIG. 4, 
panels E-G). The avascular corneas of other marine mammals 
such as dolphins (bottlenose: Tursiops truncatus; Risso's: 
Grampus griseus), and whales (Cuvier's beaked: Ziphius 
cavirostris; fin: Balaenoptera physalus; melon-headed: Pep-
onocephala electra) also contained sflt-1 (FIG. 4, panels H 
and I). The correlation between sflt-1 expression and corneal 
avascularity in diverse mammals supports an evolutionarily 
10 
conserved role for sflt-1 conferring the cloak of corneal avas-
cularity. Unlike dolphin and elephant corneas (FIG. 4, panel 
I), manatee corneas expressed mbflt-1, suggesting a splicing 
switch potentially accounting for their vascularized state. The 
15 teleological basis of the vascularized manatee cornea is 
intriguing. The absence of corneal sflt-1 and potentially sub-
optimal vision might result from a non-deleterious mutation 
in manatees as they live primarily in turbid waters. Unlike 
dugongs which are strictly marine, manatees are believed to 
20 be physiologically dependent on freshwater and CV could 
protect against, or perhaps result from, irritations of this 
hypotonic environment. 
The presence of numerous anti-angiogenic molecules in 
the cornea suggests multiply redundant mechanisms for 
25 maintaining avascularity, which is essential for optical trans-
parency and clear vision. Therefore the finding that neutral-
ization or knockdown of sflt-1 alone abolishes corneal avas-
cularity is surprising but consistent with the presence of The cornea remains avascular even in states of hypoxia 
such as those induced by eyelid closure during sleep or coma, 
and a variety of ischemic and occlusive disease states. We 30 
examined VEGF-A and sflt-1 levels in corneas of mice 
VEGF-A in the normal cornea. VEGF-A may be produced 
and held in a sequestered state by the cornea as a readily 
available store because this exposed tissue is susceptible to 
exposed to 8% 0 2 (comparable to corneal hypoxia during 
sleep) for 24 hours. Despite profound hypoxia, these corneas 
remained avascular. Although hypoxia can increase VEGF -A 
production, free VEGF-A was not significantly elevated in 
hypoxic corneas (11 ±23% greater than non-hypoxic corneas; 
P=0.78). This was attributed to a 86±34% increase in sflt-1 in 
hypoxic corneas (P=0.05), consistent with the presence of a 
hypoxia-responsive element in the flt-1 gene. These data con-
firm an important protective role upon sflt-1 in maintaining 
corneal avascularity during physiological hypoxia. In con-
trast, VEGF-A elevation without concomitant sflt-1 induc-
tion, modeled by injection of recombinant VEGF-A, was 
reversed by recombinant sflt-1/Fc administration but not iso-
type control IgG/Fc, confirming its specificity. 
The spontaneously vascularized corneas of corn! and 
Pax6+1- mice were examined for the presence of sflt-1. Cor-
neas of corn! and Pax6+1- mice, unlike those of their back-
ground strains, were deficient in sflt-1 (FIG. 4, panel A). It is 
notable that both strains have abnormalities in their corneal 
epithelium, the predominant source of sflt-1. sflt-1/Fc injec-
tion significantly reduced CV area in corn! and Pax6+1- mice 
compared to both IgG/Fc treated and untreated corneas, both 
conferring a significant role for sflt-1 in maintaining corneal 
homeostasis and suggesting the potential to clinically rescue 
CV. Although mutations in destrin, the protein altered in 
corn! mice, have not been reported in humans, Pax6 muta-
tions are present in patients with aniridia, who also have CV. 
Interestingly aniridic patient corneas were deficient in sflt-1 
compared to normal human corneas (FIG. 4, panel D). 
Florida manatees (Trichechus manatus latirostris) are the 
only organisms reported to uniformly have spontaneously 
vascularized corneas. This phenotype was also observed in 
the Antillean manatee (Trichechus manatus manatus). Inter-
estingly neither manatee cornea expressed sflt-1 whereas the 
avascular corneas of dugongs (Dugong dugan), which also 
belong to order Sirenia, and of Asian (Elephas maxim us) and 
injuries potentially requiring an angiogenic response. Alter-
natively it might be a vestigial residue of an evolutionary 
requirement to provide blood to the eye that later required 
35 biochemical compensation in the form of sflt-1 expression to 
support improved vision. 
The utilization of sflt-1 to regulate VEGF -A bioavailability 
is conserved in other systems such as cyclic vascularization 
and embryonic sprouting, and disturbances in this regulation 
40 underlie preeclampsia. The present data identifY a new role 
for sflt-1 in evolutionary establishment of optimal vision 
resulting from and requiring optical clarity. Apart from trap-
ping VEGF-A, sflt-1 can heterodimerize with mbflt-1 and 
VEGFR-2. Although neither mbflt-1 nor VEGFR-2 is 
45 expressed in the normal cornea (FIG. 1, panel G), such het-
erodimerization can modulate pathological CV. Other 
mechanisms of regulating VEGF-A bioavailability, such as 
matrix metalloproteinase-induced release, have been identi-
fied in a tumor angiogenesis model (Bergers eta!., Nat. Cell. 
50 Bioi. 2:737, 2000). 
The cornea has long been used as a readout platform to 
assay anti-angiogenic therapy in oncology, cardiovascular 
biology, and other fields. The recognition that sflt-1 is domi-
nant in maintaining corneal avascularity directly impacts the 
55 generalizability of this tissue in individual models. The 
present data elucidates the immunologic privilege of the cor-
nea as corneal avascularity is critical to the high success of 
corneal allografts. The present findings also support the use of 
sflt-1 in preventing or treating neovascularization. Further-
60 more, they illuminate its potential as a therapeutic target in 
conditions where inducing angiogenesis in a sflt-1-rich 
microenvironment might be beneficial, e.g., preeclampsia, 
wound healing, stroke, and heart disease. 
In vivo images were captured by CCD camera (Nikon) 
65 under a dissecting microscope. Blood vessels were defined by 
positive labeling with FITC-conjugated rat antibody against 
mouse CD31 (1 :333; BD Pharmingen) and negative labeling 
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with rabbit antibody against mouse LYVE-1 (1 :333; Abeam) 
on corneal flat mounts as previously reported. 
Neutralizing goat antibody (10 flg) against mouse flt-1 
(R&D Systems), isotype control goat IgG (1 0 flg; Jackson 
Immunoresearch), shRNAs (4 flg) against mbflt-1 or sflt-1, 5 
psflt-1 ( 4 flg), psflt-1 * ( 4 flg), pCre ( 4 flg), pNull ( 4 flg), 
rmVEGF-A164 (20-500 ng; R&D Systems), sflt-1/Fc (5 flg; 
R&D Systems), or isotype control IgGl/Fc (5 flg; Jackson 
Immunoresearch) were injected (2 fll) into the cornea with a 
33 gauge needle. Corneal transfection efficiency by naked 10 
plasmid of pGFP or placZ exceeded 70% as gauged by flow 
cytometry and X gal staining. Tail vein injection of clodronate 
liposomes (200 fll) and intraperitoneal injection of anti-Gr-1 
antibody (200 flg; eBioscience) were performed on each of 
the two days before and immediately after corneal injection of 15 
pshRNA sflt-1 injection to deplete peripheral monocytes/ 
macrophages and neutrophils. 
All, C57Bl/6J, corn!, Ifng-1-, ROSA26R (Gt(ROSA)26 
Sormzsor/J) lacZ reporter (The Jackson Laboratory), Vegfb_;_ 
(The Jackson Laboratory), and Balb/c mice (Harlan Labora- 20 
tories) were used. Ifnarl-1-, Pax6+1-, Pax6+1+, and Plgf_;_ 
mice have been previously described (Muller, U. eta!., Sci-
ence 264:1918, 1994; Quinn eta!., Genes Dev 10:435, 1996; 
Carmeliet eta!., Nat. Med. 7:575, 2001). flt-1 1oxP!loxP mice, 
generated and characterized by Genentech, are described 25 
elsewhere. Dolphin, dugong, elephant, human, manatee, and 
whale eyes were collected in accordance with applicable 
regulations. Experiments were approved by institutional 
review boards and conformed to the Association for Research 
in Vision and Ophthalmology Statement on Animal Research. 30 
Hypoxia was induced by placing C57Bl/6J mice into 8% 
32 
levamisole (Vector Laboratories). Immunolocalization was 
performed with rabbit antibody against the unique carboxyl-
terminus of sflt-1 (1:1000; Orecchia eta!., J. Cell Sci. 116: 
3479, 2003), rabbit antibody against the unique carboxyl-
terminus of mbflt-1 (1:1000; clone C-17, Santa Cruz 
Biotechnology), goat antibody against mouse VEGF-A 
(1:200; R&D Systems), goat antibody against human vascu-
lar cell adhesion molecule- I (1: 1 00; Santa Cruz Biotechnol-
ogy), rabbit antibody against Cre recombinase (1:5,000; 
EMD/Novagen) using biotin-streptavidin-horseradish per-
oxidase, alkaline phosphatase, or immunofluorescent meth-
ods using FITC- and PE-conjugated secondary antibodies 
(Vector Laboratories). Counter-stain was obtained with May-
er's hematoxylin (Lillie's Modified, Dako ), Nuclear FastRed 
(Vector Laboratories), or DAPI (1:25,000; Molecular 
Probes). Specificity was assessed by staining with control 
isotype non-immune IgG, omitting primary antibody, or pre-
adsorbing the primary antibody with a ten-fold molar excess 
of the immunizing peptide. 
In situ hybridization was carried out on formaldehyde fixed 
cryosections as previously described. Digoxigenin (DIG)-
labeled sense and anti-sense riboprobes were transcribed 
from mouse sflt-1 and VEGF -A cDNAs using the DIG RNA-
labeling kit (Boehringer-Mannheim). The sflt-1 probe corre-
sponded to the divergence site of sflt-1 as previously reported 
6. DIG-labeled probes were hybridized, slides were washed 
under high-stringency conditions, incubated with alkaline 
phosphatase-conjugated anti-DIG antibody (1:2000; Boe-
hringer-Mannheim), and stained with NBT/BCIP (Boe-
hringer-Mannheim). 
Cell permeable enzymatically active Cre recombinase 
(NLS-Cre) or NLS-~-galactosidase (Hare! eta!., Mol. Bioi. 
Cell. 14:4387, 2003), both containing a 6-His tag (SEQ ID 
NO: 15 and an SV 40 derived nuclear localization signal, were 
0 2 PEG ASS chambers (Columbus Instruments) for 24 hours. 
siRNA expression cassettes (SECs) were developed by in 
vitro amplification by PCR. Exemplary siRNA sequences 
include: 35 dissolved in PBS (0.6 mg/ml) and dropped on to the surface of 
the cornea at the rate of 1 fll/min for 5 min. 
AAACAACCACAAAAUACAACA (SEQ ID NO, 1) 
AATGATTGTACCACACAAAGT (SEQ ID NO, 2) 
TCTCGGATCTCCAAATTTA (SEQ ID NO, 3) 
AAAGGCTGTTTTCTCTCGGAT (SEQ ID NO, 4) 
AAAAGCACAAGGAATGATTGT (SEQ ID NO, 5) 
AAAGGCCATTTTCTCTCGGAT (SEQ ID NO, 6) 
AAAAGCAGGAGGAATGATTGT (SEQ ID NO, 7) 
It is understood that the present methods and compositions 
encompass the complement sequence of any of the above 
identified sequences. The invention also encompasses 
sequences where "U" (uracil) is substituted for "T" (thym-
ine). 
Multiple sequences were screened to identify the best tar-
gets for mbflt-1 (e.g., AAACAACCACAAAAUACAACA 
(SEQ ID NO:l)) and sflt-1 (e.g., AAUGAUUGUACCACA-
CAAAGU (SEQ ID N0:13); and UCUCGGAUCUCCA-
AAUUUA (SEQ ID N0:14)), which were ligated into the 
pSEC Neo vector. Plasmids were prepared (Plasmid Mini 
Prep kit, Eppendorf) and sequenced to confirm the in-frame 
sequence of the inserts. psflt-1 * was generated by site 
directed mutagenesis (Stratagene) of 2278-AATGATTG-
TACCACACAAAGT (SEQ ID N0:8) in psflt-1 to AAC-
GACTGCACAACTCAGAGC (SEQ ID N0:9). 
Deparaffinized sections were incubated with serum-free 
protein block (Dako or Biogenex). Endogenous peroxidase 
and alkaline phosphatase were quenched with H20 2 and 
Recombinant sflt-1/Fc or control isotype IgG 1 -Fe were 
injected (5 f.tg/2 fll) into the corneas offellow eyes of corn! (at 
2 and 3 weeks of age) and Pax6+1- (at 6 and 7 weeks of age) 
40 mice and morphometric measurements of vascularized area 
on corneal flat mounts were performed, as previously 
reported (Ambati eta!., Invest. Ophthalmol. Vis. Sci. 44:590, 
2003; Ambati eta!., Cornea 22:465, 2003), at 4 (corn!) and 8 
45 
(Pax6+1-) weeks of age. 
Enzyme-linked immunosorbent assays (ELISAs) were 
used according to the manufacturer's instructions to quantify 
sflt-1 (Quantikine, R&D Systems) and free VEGF-A 
(RELIDA, RELIATech GmbH). Measurements were normal-
ized to total protein (Bio-Rad). Immunoblotting was per-
so formed with rabbit antibody against the amino-terminus of 
flt-1 (1: 1 ,000; Angiobio ), rabbit antibodies against the unique 
carboxyl-terminus of sflt-1 (1: 100 or 1: 1,000), goat antibody 
against mouse VEGF -A (1: 1 ,000; R&D Systems), rabbit anti-
body against mouse VEGFR-2 (1:1,000; clone T014), or rab-
55 bit antibody against Cre recombinase (1: 1 0,000), and loading 
was assessed with rabbit antibody against human GAPDH 
(1 :2,000; Abeam). Mouse cornea lysates were immunopre-
cipitated with goat antibody against mouse VEGF-A (2 
f.tg/ml, R&D Systems) immobilized to protein G-agarose, 
60 subjected to SDS-PAGE, and immunoblotted with biotiny-
lated goat antibody against the amino-terminus of mouse flt-1 
(1:1,000, R&D Systems). 
Total mouse cornea RNA was prepared (RNAqueous, 
Ambion) and eDNA was synthesized by reverse transcription 
65 (TaqMan, Applied Biosystems) and analyzed by real-time 
quantitative polymerase chain reaction (ABI 7000, Applied 
Biosystems ). The primers for sflt-1 were: forward 5'-AGGT-
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GAGCACTGCGGCA-3' (SEQ ID NO:lO), reverse 5'-AT-
GAGTCCTTTAATGTTTGAC-3' (SEQ ID NO:ll). The 
primers for VEGF -A were described in Zhang eta! (Biochem. 
Biophys. Res. Commun. 292:860, 2002). FAM (6-carboxy-
fluorescein)-labeled probes (Maxim Biotech) were used as 5 
target hybridization probes. sflt-1 and Vegfa expression were 
quantified and normalized to glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) or ISS rRNA levels by polymerase 
chain reaction with reverse transcription (RT-PCR) using 
TaqMan gene expression assays (Applied Biosystems). 10 
Suspensions of cells isolated from mouse cornea by incu-
bation with collagenase D (20 U/ml; Roche Diagnostics) and 
keratanase (5 U/ml; Sigma-Aldrich) treatment were incu-
bated in Fe block (0.5 mg/ml; BD Pharmingen) for 15 min on 15 
ice. GFP expression was quantified using Alexa Fluor 488-
conjugated rabbit antibody against GFP (1:500; Molecular 
Probes). Cells were stained after fixation with 4% paraform-
aldehyde and permeabilization with 1% Triton X -100 (Sigma 
Aldrich) and were subjected to FACS analysis (FACSCalibur, 20 
BD Biosciences). Monocytes/macrophages (CDllb+ 
CD115+F4/80+) and neutrophils (CD11b+F4/80- Gr-1+), in 
cells isolated from cardiac blood after erythrocyte hemolysis 
with lysis buffer (eBioscience), were gated by FITC-conju-
gated rat antibody against mouse CDllb (1:100; eBio- 25 
science), RPE-Cy5-conjugated rat antibody against mouse 
F4/80 (1:10; Serotec), PE-conjugated rat antibody against 
mouse CD115 (1:1,000; eBioscience), and Alexa Fluor 647-
conjugated rat antibody against mouse Gr-1 (1: 1 00; eBio-
science). 30 
34 
Further, the corneal vascularization induced by sflt-1 
shRNA was not due to inflammation. Mice eyes were sys-
temically depleted of monocytes/macrophages and neutro-
phils by injection of clodronate liposomes and anti-Gr-1 anti-
body. Flow cytometry reveals the monocyte/macrophage and 
neutrophil fractions of peripheral blood leukocytes, normal-
ized to control levels, were markedly suppressed by clodr-
onate liposomes and anti-Gr-1 antibody injection compared 
to controls (PBS-liposomes and non-immune rat IgG, respec-
tively) 3 days after initial injection. *P<0.05 compared to 
controls. In addition, pshRNA-sflt-1 did not elevate VEGF -A 
mRNA levels compared to pshRNA-mbflt-1 or control unin-
jected corneas. Individual VEGF-A isoform levels measured 
by real time RT-PCR 2 days after injection were divided by 
GAPDH levels and normalized to control levels. No pairwise 
differences were statistically significant by Bonferroni cor-
rected Maun Whitney U test. 
The present data indicate that corneal vascularization 
induced by sflt-1 shRNA was specifically due to mRNA 
knockdown because p2 shRNA-sflt-1, targeted against a dif-
ferent sequence than by pshRNA-sflt-1, also induced corneal 
vascularization. In addition, the present data indicate that 
exogenous VEGF -A induces corneal vascularization by over-
whelming endogenous sflt-1. Recombinant mouse VEGF-
A164 injection induces CV in a dose-dependent mauner and 
is blocked by co-administration (5 flg) of recombinant sflt-1/ 
Fe but not isotype control IgGl-Fc. 
The present studies further found that mbflt-1 expressed in 
the Manatee cornea was inhibited by the immunizing peptide 
but not by an unrelated, negative-control peptide. 
In addition, naked plasmids are able to transfect mouse 
corneas in vivo. Flow cytometry data reveal that greater than 
70% of corneal cells express GFP 1 day after injection of 
pGFP as compared to pNull. 
Cultured mouse corneal epithelial cells were maintained in 
EMEM supplemented with 10% FCS, 1% glutamine, and 
antibiotics at 37° C. under 5% C02 . Secreted sflt-1 levels in 
the supernatant were measured by ELISA (R&D Systems) at 
0, 8 and 24 h after serum starvation. 
SiRNA Design and Synthesis: siRNAs against sFLT 
35 unique sequence (differences in bold; 3rd sequence is identi-
cal): Differences in incidence ofCV and mean levels of protein, 
mRNA, and CV area were compared with two-tailed Fisher's 
exact test and Mann Whitney U test with Bonferroni correc-
tion for multiple comparisons, respectively. P values<0.05 
were considered significant. Data are presented as 40 
mean±s.e.m. 
As previously noted, specificity of sflt-1 immunolocaliza-
tion in mouse cornea was inhibited by the immunizing pep-
tide but not by an unrelated, negative-control peptide. No 
staining was observed when anti-sflt-1 antibody was replaced 45 
with isotype control IgG or when it was omitted. 
Additional studies showed that sflt-1 was present extracel-
lularly in vivo and in vitro. The pattern of sflt-1 immunostain-
ing is diffuse and extends beyond cell borders in the superfi-
ciallayers of mouse corneal epithelium, and appears external 50 
to cytoplasm and in intercellular spaces in the deeper layers. 
Data generated from ELISA experiments demonstrated that 
mouse corneal epithelial cells constitutively secrete sflt-1. 
Further, VEGF -A produced by the cornea co localized with 
sflt-1 because immunoreactivities of sflt-1 and VEGF -A were 55 
SEQ SEQ 
Human ID Mouse ID 
AAAGGCTGTTTTCTCTCGGAT 4 AAAGGCCATTTTCTCTCGGAT 6 
AAAAGCACAAGGAATGATTGT 5 AAAAGCAGGAGGAATGATTGT 7 
AATGATTGTACCACACAAAGT 2 AATGATTGTACCACACAAAGT 2 
Provided herein are unique homologous siRNA against the 
C-terminal tail of sVEGFR 1 that suppress its secretion in 
vitro. HUVEC cells at 50% confluency were transfected with 
siRNAs against sVEGFR 1 (3 separate sequences, with high 
homology for mouse and human sVEGFR 1 targeting the 
unique C-terminal sequence) and an siRNA against GAD PH 
and incubated for 5 days. Culture medium was collected at 1, 
3, and 5 days for sVEGFR 1 expression assay by ELISA 
(R&D). siRNA-sVEGFR 1 sequence (SEQ ID N0:2) sup-
pressed the regular increase in sVEGFR 1 expression by 
64.0% over 5 days. identified as colocalizing in the mouse cornea. Moreover, 
neutralizing flt-1 protein was capable of abolishing corneal 
avascularity. Corneal injection of anti-fit-! neutralizing anti-
body (nAb) but not isotype control IgG injection elicits inva-
sionofCD31 + LYVE-1-blood vessels into cornea of mice 14 
days after injection. Western blots subsequently showed a 
shift in VEGF-A from bound to free form. 
In addition, neutralizing flt-1 gene expression abolished 
corneal avascularity. pCre but not pNull induces corneal vas-
cularization in flt-] 10xP!loxP mice. After injection, Cre is 
expressed and sflt-1 expression is reduced compared to pNull 
injection. 
As shown in FIG. 3, panel G, expression of sVEGR 1 is 
decreased by siRNA sequence provided in SEQ ID N0:2. 
Intracorneal delivery of this siRNA down-regulates unique 
6° C-terminal sequence and VEGF -binding domains of 
sVEGFR-1. Intrastromal delivery of plasmid expressing 
siRNA against the uniquely identical target sequence of 
mouse and human sVEGFR 1 into the cornea knocks down 
expression of the unique c-terminal 96 nucleotide sequence 
65 of s VEGFR 1 within 2 days. Further, expression of domains 
2-3, the VEGF-binding domains of sVEGFR 1 is also 
knocked down. FIG. 3, panel H shows suppression of unique 
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tail of sFLT by siRNA targeting (middle lane). FIG. 3, panel 
I shows suppression of mRNA of VEGF binding domains 
(553 bp) ofsFLT by siRNA targeting unique tail. Expression 
of 18sRNA control (315 bp) is unaffected. Further, FIG. 3, 
panel J shows that siRNA-sFLT decreases VEGF bound to 
sFLT and increases free VEGF in cornea. Mouse corneas 
were subjected to immunoprecipitation by antibody to sFLT 
unique tail, then underwent Western blot for VEGF (band 
visible at 25 kD). Lanes 1 and 2 are control mouse cornea: 1 
is supernatant fraction, 2 is immunoprecipitate. Lanes 3 and 4 
are from mouse corneas treated with siRNA-sFLT: 3 is super-
natant; 4 is immunoprecipitate. These data demonstrate that 
siRNA knocking down sFLT frees VEGF from sFLT seques-
tration. 
The inventors have also demonstrated that, while siRNA-
sFLT breaches corneal avascularity, it can be restored by 
co-delivery of translationally silent mutant of sVEGFR 1. 
Intrastromal delivery of plasmid expressing siRNA against 
the uniquely identical target sequence of mouse and human 
s VEGFR -1 into the cornea knocks down s VEGFR 1 expres-
sion within 2 days and stimulates blood vessel formation into 
the cornea that is spatially correlated with the injection track. 
In addition, mouse corneas 14 days post-injection with 
pSEC-siRNA-sVEGFR1 (SEQ ID N0:2) show neovascular-
ization spatially correlated with the injection track. Further, 
generation of translationally silent mutant of s VEGFR 1 was 
performed by substituting nucleotides 61-81 of this 96 nucle-
otide sequence (or 2278-2298 of the sFLT gene (sFLT=1st 6 
domains of FLT +unique tail in lieu of domain 7 of FLT) 
which normally codes for: AAT GAT TGT ACC ACA CAA 
AGT (SEQ ID NO: 2) (amino acids=NDCTTQS; SEQ ID 
NO: 12). The alternate (mutant) sequence to be substituted for 
this is: AAC GAC TGC ACA ACT CAG AGC (SEQ ID NO: 
9). Cotransfection of plasmid expressing this mutant sFLT 
along with a plasmid expressing siRNA against normal sFLT 
resulted in restoration of corneal sFLT expression and normal 
corneal avascularity. Moreover, co-injection of plasmids 
expressing siRNA-sFLT and translationally silent mutant of 
sFLT theoretically resistant to that siRNA shows expression 
of unique tail of sFLT at 2 days after injection. 
The present studies have determined that sVEGFR 1 is 
highly expressed in normal human and mouse corneal epithe-
lium and to a lesser degree in corneal keratocytes, and that 
<160> NUMBER OF SEQ ID NOS, 15 
<210> SEQ ID NO 1 
<211> LENGTH, 21 
<212> TYPE, RNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
36 
there is a preferential gradient of sVEGFR 1 in peripheral 
limbal cornea relative to sclera which would theoretically 
contribute to the limbal avascular barrier. Further, the present 
data indicates that sVEGFR 1 and VEGF which is normally 
bound to sVEGFR 1 is decreased in neovascularized human 
corneas thus identifying s VEGFR 1 as a mediator of corneal 
avascularity. 
Accordingly, provided herein are a series of nucleic acid 
molecules developed to down-regulate expression of 
sVEGFR 1 by nucleic acid interference. The unique C-termi-
10 nal tail of sVEGFR 1 was specifically targeted using a target 
sequence that is uniquely identical in the mouse and human 
gene. Transcriptional disruption of this tail also down-regu-
lates the mRNA transcript of domains 2-3 ofsVEGFR 1, its 
VEGF -binding domains, demonstrating knockdown of this 
15 gene. Delivery of a naked plasmid into the mouse cornea 
breaches corneal avascularity. This effect is reversed by deliv-
ery of a plasmid expressing a translationally silent mutant of 
s VEGFR 1. Further, corneal avascularity was not affected by 
an siRNA which down-regulates pigment epithelial derived 
factor. 
20 The selection process for siRNA screening relied on 
homology of target sequence between the mouse and human 
VEGF gene because such homology reflects evolutionary 
conservation which in turn likely indicates a target of import. 
The examples set forth above are provided to give those of 
25 ordinary skill in the art a complete disclosure and description 
of how to make and use the embodiments of the devices, 
systems and methods of the invention, and are not intended to 
limit the scope of what the inventors regard as their invention. 
Modifications of the above-described modes for carrying out 
30 the invention that are obvious to persons of skill in the art are 
intended to be within the scope of the following claims. All 
patents and publications mentioned in the specification are 
indicative of the levels of skill of those skilled in the art to 
which the invention pertains. All references cited in this dis-
35 closure are incorporated by reference to the same extent as if 
each reference had been incorporated by reference in its 
entirety individually. 
A number of embodiments of the invention have been 
described. Nevertheless, it will be understood that various 
modifications may be made without departing from the spirit 
40 
and scope of the invention. Accordingly, other embodiments 
are within the scope of the following claims. 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 1 
aaacaaccac aaaauacaac a 
<210> SEQ ID NO 2 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
21 
<400> SEQUENCE, 2 
aatgattgta ccacacaaag t 
<210> SEQ ID NO 3 
<211> LENGTH, 19 
<212> TYPE, DNA 
37 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 3 
tctcggatct ccaaattta 
<210> SEQ ID NO 4 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 4 
aaaggctgtt ttctctcgga t 
<210> SEQ ID NO 5 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 5 
aaaagcacaa ggaatgattg t 
<210> SEQ ID NO 6 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 
aaaggccatt ttctctcgga t 
<210> SEQ ID NO 7 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 7 
aaaagcagga ggaatgattg t 
<210> SEQ ID NO 8 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
38 
21 
19 
21 
21 
21 
21 
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-continued 
<400> SEQUENCE, 8 
aatgattgta ccacacaaag t 21 
<210> SEQ ID NO 9 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
oligonucleotide 
<400> SEQUENCE, 9 
aacgactgca caactcagag c 21 
<210> SEQ ID NO 10 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 10 
aggtgagcac tgcggca 17 
<210> SEQ ID NO 11 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 11 
atgagtcctt taatgtttga c 21 
<210> SEQ ID NO 12 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
peptide 
<400> SEQUENCE, 12 
Asn Asp Cys Thr Thr Gln Ser 
1 5 
<210> SEQ ID NO 13 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
oligonucleotide 
<400> SEQUENCE, 13 
aaugauugua ccacacaaag u 21 
<210> SEQ ID NO 14 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
oligonucleotide 
US 9,198,981 B2 
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-continued 
<400> SEQUENCE, 14 
ucucggaucu ccaaauuua 
<210> SEQ ID NO 15 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
19 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
6x His tag 
<400> SEQUENCE, 15 
His His His His His His 
1 5 
What is claimed is: 
1. A method of treating a condition associated with 
decreased vascularity in a subject, the method comprising 
administering to a subject in need thereof having the condi-
tion associated with decreased vascularity a compound that 
increases the bioavailability or biological activity of VEGF 
6. The method of claim 4, wherein the interfering RNA is 
20 10 to 40 nucleotides in length. 
by reducing the bioavailability or biological activity of a 25 
VEGF inactivating agent, and wherein the administering is 
sufficient to treat the condition in the subject by increasing 
vascularity, wherein the condition is selected from the group 
consisting of preeclampsia, systemic hypertension, cere-
brovascular disorders, cardiovascular disorders, peripheral 
vascular disease, vascular regeneration/recovery, and wound 30 
healing disorders and wherein the VEGF inactivating agent is 
fms-like tyrosine kinase is soluble flt-1 (sflt-1) or membrane 
bound flt-1 (mbflt-1 ), and wherein the compound is a nucleic 
acid molecule. 
2. The method of claim 1, wherein the VEGF is selected 35 
from the group consisting ofVEGF-A, VEGF-B, VEGF-C 
andVEGF-D. 
7. The method of claim 1, wherein the expression of the 
agent is reduced by an inducible excision system. 
8. The method of claim 7 wherein the inducible excision 
system is ere-lox or FLP/FRT excision system. 
9. The method of claim 7, wherein excision is facilitated by 
the introduction of exogenous CRE recombinase. 
10. The method of claim 9, wherein the introduction is by 
the topical application ofNLS-Cre. 
11. The method of claim 1, wherein the compound is 
administered via a topical, intravenous, oral, or intracanali-
cular route. 
12. The method of claim 1 wherein the condition is preec-
lampsia. 
13. A method of treating preeclampsia in a subject, the 
method comprising administering to a subject in need thereof 
a compound that increases the bioavailability or biological 
activity ofVEGF by reducing the bioavailability or biological 
activity of a VEGF inactivating agent, wherein the VEGF 
3. The method of claim 1, wherein the compound com-
prises a double stranded nucleic acid molecule having one 
strand that is at least 95% complementary to at least a portion 
of a nucleic acid sequence encoding the agent. 
4. The method of claim 3, wherein the nucleic acid mol-
ecule comprises an interfering RNA molecule. 
5. The method of claim 4, wherein the interfering RNA 
molecule is selected from the group consisting of shRNA, 
siRNA and miRNA. 
40 inactivating agent is fms-like tyrosine kinase is soluble flt-1 
(sflt-1) or membrane bound flt-1 (mbflt-1 ), wherein the com-
pound is a nucleic acid molecule and wherein the nucleic acid 
molecule is administered in an amount that is sufficient to 
increase vascularity in the subject. 
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